Mark D. Nielsen, Esq., CA Bar No. 210,023
mark.nielsen@solidcounsel.com
SCHEEF & STONE, LLP
2600 Network Boulevard, Suite 400
Frisco, Texas 75034
Telephone: (214) 472-2100
Fax: (214) 472-2150

Daniel M. Cislo, Esq., CA Bar No. 125,378
dan@cislo.com
C. Wook Pak, Esq., CA Bar No. 244,780
wpak@cislo.com
CISLO & THOMAS LLP
12100 Wilshire Boulevard, Suite 1700
Los Angeles, California 90025
Telephone: (310) 451-0647
Fax: (310) 394-4477

Attorneys for Plaintiff,
Nanjing Nutrabuilding Bio-Tech Co., Ltd.

UNITED STATES DISTRICT COURT

CENTRAL DISTRICT OF CALIFORNIA

NANJING NUTRABUILDING BIO-TECH CO., LTD., Plaintiff, vs. BONERGE LIFESCIENCE (HUNAN) CO., LTD., and DOES 1-9, INCLUSIVE, Defendants.	Case No. **COMPLAINT FOR PATENT INFRINGEMENT** **[DEMAND FOR JURY TRIAL]**

COMPLAINT FOR PATENT INFRINGEMENT

For its complaint, Plaintiff Nanjing Nutrabuilding Bio-Tech Co., Ltd. alleges as follows:

PARTIES

1. Plaintiff Nanjing Nutrabuilding Bio-Tech Co., Ltd. ("Plaintiff" or "NNB") is a company organized under the laws of the People's Republic of China with a place of business at No. 270 Jiqingmen Street, Suning Huigu, Building E6, Room 2105, Nanjing, China 210017.

2. Defendant Bonerge Lifescience (Hunan) Co., Ltd. ("Defendant" or "Bonerge") is a business entity, on information and belief, formed under the laws of the People's Republic of China, with a place of business in this judicial district at 2049 S. Hellman Ave, Unit A, Ontario, California 91761. In addition, Bonerge may have places of business having the addresses of either Bldg # 7B, Depu Parkview, E&D Zone, Changsha, Hunan China 414000, or Room 102, Building 7, Depu Wuhe Enterprise Park, Changsha City, Hunan, China, or Room 102, Building 7, Phase 1, Depu Wuhe Enterprise Park, No.1, NO.3 LuoSitang Road, Changsha, Hunan, Changsha, Hunan 410000, CN, which each may be the same location.

3. The true names and capacities, whether individual, corporate, or otherwise of Defendants Does 1-9 inclusive, are unknown to Plaintiff, who therefore sues them by such fictitious names. Plaintiff will seek leave to amend this complaint to allege their true names and capacities when they have been ascertained. Plaintiff is informed and believes and thereon alleges that each of the fictitiously named Defendants is responsible in some manner for the occurrences herein alleged. At all times herein mentioned, Defendants Does 1-9 inclusive were the agents, servants, employees or attorneys of their co-defendants, and in doing the things hereinafter alleged were acting within the course and scope of their authority as those agents, servants, employees or attorneys, and with the permission and consent of their co-

defendants.

JURISDICTION AND VENUE

4. This Court has subject matter jurisdiction over this action pursuant to 28 U.S.C. § 1331 and § 1338(a) as it arises under Acts of Congress related to patents.

5. On information and belief, Bonerge attended and exhibited (in Booth 4182) the Natural Product Expo West trade show in this judicial district in Anaheim, California to promote its products, including the product accused herein of infringing NNB's patent. Bonerge posted an article on its website on or about April 28, 2024 about its attendance at this show. See https://bonerge.com/site-List-7.html and https://bonerge.com/index/Article/show/cat_id/7/id/24. *See* **Exhibits 1-2**, attached hereto.

6. Bonerge, holding themselves out as Bonerge Lifescience on LinkedIn also posted about its attendance at the Nature Product Expo West, including referencing the accused product in this case. On information and belief, the trade show referenced by Bonerge occurred on or about March 13-16, 2024 in this judicial district at the Convention Center in Anaheim, California. *See* **Exhibits 3-5**, attached hereto.

7. Also, according to Bonerge's LinkedIn page, it has "associated members" in this judicial district, including Jack Chen. Jack Chen's LinkedIn page indicates he is in Los Angeles, California. *See* **Exhibits 6-7**, attached hereto.

8. In addition, in a press release by Bonerge dated July 31, 2024, Bonerge identifies as its "Contacts" a Cecilia Yang having an email address of sales@bonerge.com and a telephone number of (949) 712-7328, and (949) is an Orange County, California area code. *See* **Exhibit 8**, attached hereto.

9. Furthermore, on Bonerge's website (www.bonerge.com), the footer of most, if not every, page of the website appears as follows,



and contains contact information that precisely corresponds to Cecilia Yang's contact information on Bonerge's press release referenced above in Exhibit 8. The same footer also contains an address in this judicial district at 2049 S. Hellman Ave, Unit A, Ontario California 91761. Thus, Bonerge has a physical presence in this judicial district. The "Contact" tab on Bonerge's website also contains the same information. *See* **Exhibit 9**, attached hereto.

10. The foregoing demonstrates that Bonerge actively markets, offers to sell, and on information and belief, sells its products in and through this judicial district, including the accused dihydroberberine product; and, it does so with full understanding and intention that its dihydroberberine product will be compounded into tablets or capsules and used in product sold by its customers to end users for purposes of managing glucose tolerance, managing blood glucose levels, related metabolic benefits, and weight loss.

11. Accordingly, this Court has personal jurisdiction over Bonerge in that, on information and belief, Bonerge has committed, and continues to commit, acts of direct and/or indirect infringement in violation of 35 U.S.C. § 271 in this judicial district, by having a physical presence in this judicial district at 2049 S. Hellman Ave, Unit A, Ontario California 91761, by placing products, including the accused infringing product, into the stream of commerce from this judicial district, with the knowledge and understanding that such products are used, imported, offered for sale, and/or sold in this judicial district and elsewhere in the U.S.

12. Venue is proper in this judicial district as to Bonerge pursuant to 28 U.S.C. § 1400(b) in that Bonerge resides in this judicial district at 2049 S. Hellman Ave, Unit A, Ontario California 91761 and/or Bonerge has committed acts of

infringement in this judicial district as detailed herein, and has a regular and established, physical place of business in this judicial district at 2049 S. Hellman Ave, Unit A, Ontario California 91761. On information and belief, the accused product referenced herein is at least imported, shipped to, stored in, and shipped from Bonerge's facility in Ontario, California to customers in the U.S., including at least, on information and belief, Nature's Fusions of Orem, Utah.

FACTUAL ALLEGATIONS

13. NNB owns United States Patent No. 10,278,961 (the "'961 Patent") by virtue of several assignments. The '961 Patent is attached hereto as **Exhibit 10**. The '961 Patent may also be referred to herein as the "patent-in-suit."

14. The '961 Patent, entitled "Administration of Berberine Metabolites," which issued on May 7, 2019, was filed on April 19, 2017 as U.S. Patent Application No. 15/291,933, which itself claims priority to U.S. Provisional Application No. 62/324,794, filed on April 19, 2016.

15. The patent-in-suit describes berberine metabolites, including dihydroberberine, and its administration of pharmaceutically effective amounts of berberine metabolites, including dihydroberberine, to manage and improve glucose tolerance and related metabolic issues (e.g., metabolic syndrome).

16. On or about September 12, 2024, NNB, through counsel, provided written notice of the infringement of the patent-in-suit via a letter to Bonerge. *See* **Exhibit 11**, attached hereto. The letter was delivered to Bonerge on or about September 25, 2024.

17. On or about October 29, 2024, NNB, through counsel, sent a second letter to Bonerge regarding allegations of infringement of the patent-in-suit by Bonerge. *See* **Exhibit 12**, attached hereto.

18. To the best of NNB's knowledge, Bonerge did not respond to either of these letters.

19. On or about November 5, 2024, NNB, through counsel, provided written notice of the infringement of the patent-in-suit via a letter attached to an email to Nature's Fusions or Orem, Utah. *See* **Exhibit 13**, attached hereto. Exhibit 14, *infra*, shows the emailing of this letter on November 5, 2024.

20. On or about November 6, 2024, Nature's Fusions, in turn, via email from Matt Peterson (matt@naturesfusions.com) to NNB's counsel added a representative of Bonerge to the email thread (allen.g@bonerge.com) and stated in part to NNB's counsel, "You can speak with the manufacturer of the ingredient we use in our product. Allen from Bonerge." *See* **Exhibit 14**, attached hereto.

21. The next day (November 6, 2024), Matt Peterson further responded and added Cecilia.Y@bonerge.com to the email thread and stated, "Cecilia from our manufacturer, who has also worked extensively with U.S. patent laws, is copied here and available for further questions." *See* **Exhibit 14**.

22. Accordingly, multiple representatives of Bonerge were given actual notice of the accusations of infringement of one or more of the claims of the '961 Patent by no later than November 6, 2024, but more likely by no later than on or about September 25, 2024.

23. On information and belief, Bonerge makes, uses, imports, offers to sell, and/or sells its dihydroberberine product in the U.S. with full understanding and intention that its dihydroberberine product will be compounded into tablets or capsules and used in product sold by its customers to end users for purposes of managing glucose tolerance, managing blood glucose levels, related metabolic benefits, and weight loss. *See* **Exhibits 15-18**, attached hereto.

24. By way of example only, and without waiving any right to assert infringement of any other claim of the '961 Patent either directly or indirectly, claim 1 reads: "A method of managing glucose tolerance in an individual, the method comprising: administering, to an individual, a pharmaceutically effective amount of dihydroberberine, wherein the pharmaceutically effective amount of

dihydroberberine comprises approximately 25 mg to approximately 800 mg of dihydroberberine."

25. By way of example only, and without waiving any right to assert infringement of any other claim of the '961 Patent either directly or indirectly, claim 2 reads: "The method of claim 1 wherein the administration of dihydroberberine reduces fasting glucose levels."

26. By way of example only, and without waiving any right to assert infringement of any other claim of the '961 Patent either directly or indirectly, claim 5 reads: "The method of claim 1 wherein the dihydroberberine is orally administered as a capsule or tablet."

27. By way of example only, and without waiving any right to assert infringement of any other claim of the '961 Patent either directly or indirectly, claim 7 reads: "The method of claim 1 wherein the dihydroberberine is administered at least once daily."

28. On information and belief, Bonerge imports dihydroberberine into the U.S., stores it at its location in Ontario, California, takes orders from customers (e.g., Nature's Fusions), and ships the dihydroberberine product from its Ontario, California facility to its customers. And, Bonerge at all relevant times herein has done, and does so, knowing full well how its customers and end users will use the dihydroberberine (e.g., as a supplement for healthy metabolism, weight loss, blood sugar control), and intending for the same to occur. Bonerge markets its dihydroberberine product under the name GLUCOSOBER and at all relevant times herein has known, knows, and continues to know full well that dihydroberberine is used to control glucose levels, manage glucose tolerance, and support healthy metabolism. In its federal trademark application for GLUCOSOBER, the identification of goods states:

> Dietary beverage supplements for human consumption in liquid and dry mix form for therapeutic purposes; Dietary

supplement drink mixes; Dietary supplemental drinks; Dietary supplements; Dietary supplements for animals; Dietary supplements for humans; **Dietary supplements for lowering glucose levels**; Dietary supplements in the form of capsules, tablets, caplets, powder, liquids, syrups, gummies, gels and soft chews; **Dietary supplements in the nature of weight loss powders**; Dietary and nutritional supplements; **Dietary and nutritional supplements used for weight loss**; Dietary food supplements; Food supplements; Herbal supplements; Meal replacement bars for weight loss purposes; Nutritional food additives for medical purposes in the nature of natural food extracts derived from plants, fruits and vegetables; Nutritional supplements; **Nutritional supplements for lowering glucose levels**; Nutritional supplements in the form of capsules, tablets, caplets, powder, liquids, syrups, gummies, gels and soft chews; Plant extracts, other than essential oils, for medical, veterinary and pharmaceutical purposes; Plant extracts, other than essential oils, for pharmaceutical purposes; Plant and herb extracts, other than essential oils, for medicinal purposes; Powdered nutritional supplement concentrate; Powdered nutritional supplement drink mix; **Glucose dietary supplements**; Natural dietary supplements; Nutraceuticals for use as a dietary supplement; Nutritional and dietary supplements formed and packaged as bars; Nutritional supplement meal replacement bars for boosting energy; Vitamins and dietary food supplements for animals.


See **Exhibit 19**, attached hereto (emphasis added).

29. In addition, inasmuch as Nature's Fusions has admitted that its dihydroberberine manufacturer is Bonerge, Natures Fusions' website recently included a photograph of the bottle of its dihydroberine-containing product as follows (*see* **Exhibits 20-21**, attached hereto):





30. Thus, Nature's Fusions' product is labeled and marketed consistent with Bonerge's statements about dihydroberberine, including the following:



The Detail

Dihydroberberine Helps To Improve Glucose and Lipid Metabolic Health

Until now, there are large amounts of scientific research showing that in reduce blood sugar levels; promote lipid conversion; help for loss weight, **Dihydroberberine(DHB) has better effect than Berberine(BBR).**

1. Maintain Blood Sugar Standard

BBR has been showen to adjust Sugar metabolism in human body through reduced glucose absorption; inhibit gluconeogenesis; regulate insulin levels; active PKC and AMPK.

DHB shows better effect than BBR in adjust sugar metabolism, a study, which the subjects were mice shows BBR and DHB all can improve 44% insulin sensitivity. Compared with DHB and BBR for improving insulin sensitivity. The results shows that to cause the same reaction with DHB, you need five times more than BBR.

2. Lipid Metabolism

The effect of BBR on fat loss is thought to be related to the improvement of insulin sensitivity and the activation of AMPK enzyme. In addition, BBR has been shown to lower cholesterol levels and thus reduce the risk of heart disease, this is thought to be caused by BBR's inhibitory effect on an enzyme called PCSK9, which when inhibited causes more LDL (bad cholesterol) to be removed from the blood.

One study compared the pancreatic lipase inhibition of BBR and DHB, the results shows that because of the affinity of DHB is stronger than BBR, the BBR has a lower inhibitory action compared to DHB on pancreatic lipase.

3. Weight Loss and Prevent Obesity

BBR can regulate blood glucose and lipid balance in many ways, indicating that it can help regulate body weight. In one study, subjects were given BBR over time, after 12 weeks, their BMI levels dropped from 31.5 to 27.4. DHB has stronger ability in these aspect,so DHB may be considered a more effective weight-loss aid than BBR.

From: https://www.bonerge.com/index/Article/show/cat_id/10/id/1 (accessed January 22, 2025).

31. Bonerge at all relevant times has been fully aware of the glucose management efficacy of berberine and dihydroberberine and has intentionally marketed its dihydroberberine product to supplement sellers such as Nature's Fusions in order to induce them to formulate it into dihydroberberine-containing supplements in the form of capsules or tablets, for example, to then be sold to end users in the U.S. to enable them to manage their own glucose tolerance and/or reduce fasting glucose levels. In other words, Bonerge is knowingly and intentionally inducing and/or contributing to the infringement of one or more of the claims of the '961 Patent by selling a product it knows will be administered by end users to manage their own

glucose tolerance and/or reduce fasting glucose levels.

32. NNB has not licensed or otherwise authorized Bonerge (or its dealers, distributors, customers, affiliates, or the like) to make, use, import, offer to sell, and/or sell dihydroberberine-containing supplements used for managing glucose tolerance and/or reduce fasting glucose levels. In other words, the making, using, importing, offering to sell, and/or selling of dihydroberberine-containing supplements used for managing glucose tolerance and/or reduce fasting glucose levels by Bonerge (or its dealers, distributors, customers, affiliates, or the like) is unauthorized.

33. Bonerge's infringement of the patent-in-suit is willful. Bonerge has known about the '961 Patent since at least as early as November 6, 2024, but more likely since on or about September 25, 2024, and is not known to have altered its infringing product/system or activities, or the advertising, marketing, and/or promotion thereof with respect its infringing product/system since that time.

34. Bonerge is therefore liable to NNB for money damages pursuant to 35 U.S.C. § 284 from at least as early as November 6, 2024, but more likely since on or about September 25, 2024, if not the issue date of the '961 Patent. In addition, Bonerge must be deterred from any further violations of NNB's rights in the patent-in-suit through a permanent injunction. Bonerge should also be required to pay NNB's attorneys' fees, expenses, and costs for its willful and blatant disregard of NNB's patent rights.

COUNT I – PATENT INFRINGEMENT – U.S. PATENT 10,278,961

(35 U.S.C. §§ 101 et seq.)

35. NNB hereby repeats and incorporates herein by reference the allegations set forth in paragraphs 1 through 34 above.

36. NNB's '961 Patent (*see* **Exhibit 10**) has at all relevant times subsequent to its issue date been fully enforceable and is now fully enforceable.

37. Subsequent to the issuance of the '961 Patent, Bonerge has directly and/or indirectly infringed the '961 Patent by making, using, importing, offering to sell, and/or selling, and continuing to make, use, import, offer to sell and/or sell dihydroberberine-containing supplements used for managing glucose tolerance and/or reduce fasting glucose levels, which come within the scope of at least one claim of the '961 Patent, and/or that come within a range of equivalents of at least one claim of the '961 Patent, intentionally inducing and/or contributing to the infringing activities of others in the form of their use of dihydroberberine-containing supplements used for managing glucose tolerance and/or reduce fasting glucose levels, as well as the administration by end users of the dihydroberberine-containing supplements used for managing glucose tolerance and/or reduce fasting glucose levels.

38. The making, using, importing, offering to sell, and/or selling of the accused product(s) by Bonerge, including in, from, and/or through its distribution facility in Ontario, California, and/or contributing to and/or inducing the infringing activities of others (including through at least advertising, marketing, promotion, and instructions and information provided to end users and/or installers on, for example, Bonerge's website, product literature), has been without authority or license from NNB and is in violation of NNB's rights under the '961 Patent, thereby infringing the '961 Patent.

39. As set forth above, Bonerge was put on notice of the '961 Patent and its infringement since at least as early as September of 2024, and for at least the same amount of time, Bonerge has been aware of and extensively promoted the use of dihydroberberine in connection with managing glucose tolerance and/or reduce fasting glucose levels, and has encouraged the use of dihydroberberine for those purposes.

40. For the reasons stated elsewhere herein, Bonerge's infringement of NNB's '961 Patent has been, and is, willful, with knowledge of, and in disregard for

the exclusive rights of NNB set forth in its '961 Patent.

41. The amount of money damages due NNB as a result of Bonerge's infringing acts will be determined according to proof at trial, with NNB being entitled to damages adequate to compensate it for the infringements, but in no event less than a reasonable royalty.

42. The harm to NNB arising from Bonerge's acts of infringement of NNB's '961 Patent is not fully compensable by money damages. Rather, NNB has suffered and continues to suffer irreparable harm which has no adequate remedy at law and which will continue unless Bonerge's conduct is enjoined. NNB is therefore also entitled to a preliminary injunction, to be made permanent on entry of the judgment, preventing Bonerge from further acts of infringement.

PRAYER FOR RELIEF

WHEREFORE, NNB demands judgment against Bonerge, as follows:

A. A finding that Bonerge has directly and/or indirectly infringed the patent-in-suit.

B. For an order preliminarily and permanently enjoining Bonerge, and its officers, directors, agents, servants, customers, distributors, re-sellers, affiliates, employees, and contractors, and all other persons acting in concert with it from committing any further acts of infringement, including but not limited to, manufacturing, using, importing, offering to sell, and selling dihydroberberine-containing supplements used for managing glucose tolerance, supporting healthy metabolism, and/or reduce fasting glucose levels, contributing to, inducing, or otherwise aiding, abetting, or assisting others in such infringing activities;

C. For an order directing Bonerge to file with this Court and to serve on NNB within thirty (30) days after service on Bonerge of the injunction granted herein, or such extended period as the Court may direct, a report in writing, under oath, setting forth in detail the manner and form in which Bonerge has complied with the

injunction and order of the Court;

D. For a judgment to be entered for NNB against Bonerge awarding damages adequate to compensate NNB for the infringement, but in no event less than a reasonable royalty;

E. For a judgment awarding to NNB prejudgment and postjudgment interest until the award is fully paid;

F. For a judgment that Bonerge has willfully and deliberately infringed NNB's patent rights, such that it is determined that this is an exceptional case entitling NNB to enhanced damages under the Patent Laws of the United States;

G. For an award to NNB of costs, expenses, and attorneys' fees, incurred in bringing this action under the Patent Laws of the United States; and,

H. For such other and further relief as this Court may deem just and equitable under the circumstances.

Respectfully submitted:
SCHEEF & STONE LLP

Dated: January 31, 2025

By: /s/ Mark D. Nielsen
Mark D. Nielsen

CISLO & THOMAS LLP
Daniel M. Cislo
C. Wook Pak

Attorneys for Plaintiff,
NANJING NUTRABUILDING BIO-TECH CO., LTD.

DEMAND FOR JURY TRIAL

NNB hereby demands a trial by jury on all issues raised by the Complaint so triable.

Respectfully submitted:
SCHEEF & STONE LLP

Dated: January 31, 2025

By: /s/ Mark D. Nielsen
Mark D. Nielsen

CISLO & THOMAS LLP
Daniel M. Cislo
C. Wook Pak

Attorneys for Plaintiff,
NANJING NUTRABUILDING BIO-TECH CO., LTD.

EXHIBIT 1

BONERGE

CONTACT

NEWS AND ARTICLES



05-05 , 2024

Recap of SSE Exhibition

Bonerge looks forward to continuing this journey of discovery and growth with you, and we eagerly anticipate the opportunity to reconnect at future exhibitions.

NNB Exh. 2147, p. 017

BONERGE

CONTACT



04-28 , 2024

Bonerge Shines at Natural Product West with BeFisetin Debut

Recalls for Natural Product Expo 2024 and we are looking firward to meeting you next year

LEARN MORE

BONERGE

CONTACT



04-28 , 2024

Navigating the Frontier of Healthy Aging: Insights from the CHL Scientific Conference

Join Bonerge as we explore anti-aging supplements, featuring leading scientists, innovative ingredients, and vibrant discussions.

LEARN MORE

BONERGE

CONTACT



10-24 , 2023

Discover our Nutritional Ingredients at SSW!

Meet Bonerge at SupplySide West. Booth #7132

LEARN MORE

BONERGE

CONTACT



08-05 , 2023

Why is BeFisetin™ called the standard of Fisetin?

Definitely, no one denies the importance of quality in the dietary ingredients industry. The manufacturers, the sellers, the consumers, etc. all care about the quality of dietary ingredients.

LEARN MORE

BONERGE

CONTACT



08-05 , 2023

Bonerge guarantees its customers, its employees, and nature free from methanol.

We all know that methanol is a harmful solvent frequently used in the extraction process of botanical products for its good solubility and relatively low cost...

LEARN MORE

BONERGE

BONERGE

CONTACT

Quick Links

About Us
BongeLov System
News & Articles
BeFisetin

Our Products

Branded Ingredients
Featured Ingredients
Classic Ingredients

Disclaimer: All health claims are based on scientific research and are not intended to diagnose, cure or prevent any disease.

Contact Info

2049 S. Hellman Ave, Unit A, Ontario CA 91761, USA

+1 (949) 712-7328

sales@bonerge.com

Join us

EXHIBIT 2

Bonerge Shines at Natural Product West with BeFisetin Debut

We're excited to share with you the highlights from our recent participation at the Natural Product West exhibition in Anaheim! Bonerge garnered a lot of attention from attendees, with our flagship product, StanYouth Fisetin Extract, making its debut at the event.

BeFisetin, our premium branded fisetin, represents Bonerge's commitment to pursuing high-quality, safe ingredients. It has a total flavonoid content greater than 99%, Fisetin content greater than 98% and total impurities smaller than 1%. We are the only Branded Fisetin at the exhibition, capturing the interest of many visitors.

As the global population ages and consumer need for healthy lifestyles continues to rise, the need for anti-aging supplements is on the rise. At Natural Product West, our longevity and metabolism-boosting products received considerable interest and inquiries.


Our featured products

Urolithin A, known for its unique mitophagy effects, Urolithin A helps maintain mitochondrial health. Studies have shown its ability to prolong the lifespan of animals and enhance muscle levels and sports performance across all age groups.

plants that effectively clears senescent cells and reduces inflamma
body. Given that senescent cells accumulate with age and are present in multiple organs, fisetin's role in combating aging is indispensable.

Dihydroberberine (DHB): Offering more direct absorption compared to Berberine. Berberine is popular for its weight loss benefits, but its absorption has been suboptimal. Studies indicate that after the oral administration of DHB and berberine, DHB achieves higher blood concentrations, demonstrating greater bioavailability.

During the exhibition, our team engaged in insightful discussions, forging valuable connections with peers, brands, and potential collaborators. It was inspiring to witness the growing interest for our products and the positive impact they can have.



Looking ahead, Bonerge remains persistent in our commitment to innovation. We are continuously exploring new aspects for product development, innovative dosage forms, and our formulations to ensure improved efficacy and customer satisfaction.

We extend our gratitude to everyone who visited our booth, engaged with our team, and expressed interest in our products. If we didn't have the opportunity to

BONERGE

CONTACT


No.4182
BeFisetin Be Golden Standard of Fisetin
FISETIN, THE BEST BOTANICAL SENOLYTIC FOR HEALTHY AGING !
BONERGE
INGREDIENTS LIST
Fisetin Liposome
Berberine Liposome
Berberine HCl
Dihydroberberine
Golden Oyster Mushroom Extract
Urolithin A
Urolithin A-diacetate
Apigenin
Spermidine
PQQ
Dihydroquercetin
NMN / NR / NAD
Huperzine A 1%
Black Ginger Extract
Zhoukou Zhiyuan Gelatin Trade Co., Ltd
COLLAGEN PEPTIDE & GELATIN
Manufacturer of Collagen Peptide
Manufacturer of GELATIN
Manufacturer of Non-dairy creamer
BeFisetin
BeFisetin® Ultra99
BE GOLDEN STANDARD OF FISETIN

BONERGE

CONTACT

BONERGE

Bontanical Energy for Healthy Aging
Quality,Safety and Love of Life

Quick Links

About Us
BongeLov System
News & Articles
BeFisetin

Our Products

Branded Ingredients
Featured Ingredients
Classic Ingredients

Disclaimer: All health claims are based on scientific research and are not intended to diagnose, cure or prevent any disease.

Contact Info

2049 S. Hellman Ave, Unit A, Ontario CA 91761, USA

+1 (949) 712-7328

sales@bonerge.com

Join us

EXHIBIT 3

informa

New Exhibitor Application (https://web.archive.org/web/20240216163529/https://standards.newhope.com/new-exhibitor-application/) | Exhibitor Console (Login Required) (https://web.archive.org/web/20240216163529/https://exhibitor.expowest.com/ew24/Public/e_Login.aspx?_gl=1*jt3z2l*_gcl_au*ODU0MTM5MzU4LjE2OTI4MDIyNzI) | Contact (https://web.archive.org/web/20240216163529/https://www.expowest.com/en/contact.html)

Natural Products EXPO WEST®
(/web/20240216163529/https://www.expowest.com/content/informa/npe-west/en/home.html)



Empower Your Future!

Natural Products Expo West is the leading trade show in the natural, organic, and healthy products industry where you can unearth your next big seller among the largest collection of emerging and pioneering brands. **NEW to 2024**: Buyer-Only Hours | Wednesday, March 13, 12:00 - 1:00pm | ACC Level 3 & North Halls

Get ready to be inspired through product discovery, elite education, and sustainable innovation!

Prices increase on March 11th! **Register (https://web.archive.org/web/20240216163529mp_/https://www.xpressreg.net/register/NPEW0324/start.asp?reportSuite=informaexpowest&utm_source=Direct&utm_medium=Direct&utm_campaign=Unspecified&utm_content=&utm_term=&utmMDMContactID=&PromoCode=&formId=null&formName=HLN24EWE-Xpressreg-Registration&formType=Visitor-Registration&reportSuite=informaexpowest&utm_source=undefined&utm_medium=&utm_campaign=&utm_content=&utm_term=&utmMDMContactID=&PromoCode=&formId=null&formName=HLN24EWE-Xpressreg-Registration&formType=Visitor-Registration)** today to get Advanced Pricing!

Book Your Hotel
(/web/20240216163529/https://www.expowest.com/en/venue-travel/hotel-and-flight.h

Subscribe for Updates
(https://web.archive.org/web/20240216163529/https://www.expowest.com/en/subscr

Education & Events

March 12-16, 2024

Trade Show

ACC Level 3 & North Halls
March 13-15, 2024

ACC Halls A-E & Arena
March 14-16, 2024

Anaheim Convention Center
Anaheim, CA

March 12-16, 2024

(https://web.archive.org/web/20240216163529/https://www.google.cc
sa=X&ved=2ahUKEwjt9M6RudPlAhXEqFkKHV8WAj8Q_BIwFHoECAsQC
Anaheim, CA USA

(https://web.archive.org/web/20240216163529/https://www.linkedin.com/showcase/natural-products-expo/)

(https://web.archive.org/web/20240216163529/https://www.instagram.com/natprodexpo/)

(https://web.archive.org/web/20240216163529/https://www.youtube.com/NewHopeNaturalMe



(https://web.archive.org/web/20240216163529/https://expowest24.smallworldlabs.com/exhibitors

Exhibitor List ▸



(https://web.archive.org/web/20240216163529/https://www.expowest.com/en/events-education/events.html)

Events ▸



(https://web.archive.org/web/20240216163529/https://expowest24.smallworldlabs.com/sessions)

Education ▸



Watch The Video
(https://web.archive.org/web/20240216163529/https://youtu.be/6a__WYwkd0E)

Sponsors (https://web.archive.org/web/20240216163529/https://www.expowest.com/en/sponsors.html)

#EXPOWEST



(https://web.archive.org/web/20240216163529/https://www.instagram.com/natprodexpo/)

(https://web.archive.org/web/20240216163529/http://www.newhope.com/)

(https://web.archive.org/web/20240216163529/https://www.newhope.com/sign-industry-e-newsletters-new-hope)

This event is my favorite trade show and makes my year brighter to attend.

— Dennis Knicely, Healing News Network

(https://web.archive.org/web/20240216163529/https://www.nbjsummit.com/)

(https://web.archive.org/web/20240216163529/https://www.newhope.com/)

(https://web.archive.org/web/20240216163529/https://www.expowest.com/fresh-ideas/en/home.html)

Beacon DISCOVERY™ BY NEW HOPE NETWORK

(https://web.archive.org/web/20240216163529/https://beacon.newhope.com/)

informa markets

(https://web.archive.org/web/20240216163529/http://www.informamarkets.com/)

Copyright © 2024. All rights reserved. Informa Markets, a trading division of Informa PLC.

[redacted]

EXHIBIT 4

Your search produced the following search result(s) for these filters:
Category: Raw Ingredients (Bio-metabolites/Intermediates)

Refine Search

COMPANY NAME	BOOTH#
American HuaYi Co.	5104
BioGin Health Co.,Ltd.	4056
Bonerge Lifescience(Hunan) Co., Ltd	4182
Enzymeking Biotechnology	N1343
EpiCor Postbiotic (a Cargill brand)	3711
Euromed USA, Inc.	3925
Fytexia	3674
Ingia Bio	4077
Ingredalia SL	5121
Kyowa Hakko USA	4127
Shandong Longzen Pharmaceutical Co., Ltd.	3444
Yuen Diing Enterprise, dba Frusirnag	3242

EXHIBIT 5

LinkedIn

Join now Sign in

Articles People Learning Jobs Games Get the app

Bonerge Lifescience 's Post

Bonerge Lifescience
78 followers
10mo · Edited

Reflecting on an incredible experience at the latest Nature Product Expo West experience! #expowest2024

It was truly a pleasure to be part of this year's EXPO WEST! A huge thank you to everyone who visited our booth, your support means the world to us.

After years of researching and improving, our featured products, #Fisetin, #Urolithin A, and #Dihydroberberine, have truly taken the spotlight at this event. The senolytics effects of Fisetin and the autophagy effect of Urolithin A are providing anti-aging markets with new choices. Brands are actively seeking innovative, high-quality longevity ingredients. Our quality-based, ultrapure products are catering to the rapidly growing demands.

Moreover, our #Liposome products have garnered much attention, with Liposome Berberine, Liposome Urolithin A, Liposome Fisetin, and Liposome Vitamin C. We received many inquiries for more product details. Our Liposome Urolithin A is highly biocompatible with improved bioavailability than regular Urolithin A. This further expands the applications of the hot product. Liposome Berberine has increased absorption and safety through high bioavailability and food-grade raw materials like sunflower lecithin. The daily dosage of Berberine is increased from 300mg to 1500mg per day, but no any human safety study of the safety of this high dosage and no long use of this high dosage, liposome Berberine is a good solution Liposome Berberine allows consumers to obtain the benefits of Berberine while avoiding excessive dosages and associated side effects. Please don't hesitate to reach out and continue our discussion at EXPO.

We decided to attend this show at the very last minute and we're making next year's #npew even better, with more preparations. Stay tuned for more updates and more novel products!



1

Like Comment Share

To view or add a comment, **sign in**



78 followers

View Profile + Connect

More from this author



About Bonerge: Who we are, What we do, and Why choose us

Bonerge Lifescience · 1y

Explore topics

- Sales
- Marketing
- IT Services
- Business Administration
- HR Management
- Engineering
- Soft Skills
- See All

© 2025

About

Accessibility

User Agreement

Privacy Policy

Your California Privacy Choices

Cookie Policy

Copyright Policy


Brand Policy


Guest Controls

Community Guidelines

Language

EXHIBIT 6


Home
My Network
Jobs
Messaging
Notifications
Me
For Business
Try Premium for $0
Bonerge Lifescience
Message
Follow
Home
About
Posts
Jobs
People
BONERGE
Bonerge Lifescience
Quality, Safety, Love of life
Food and Beverage Manufacturing
Changsha, Hunan · 77 followers · 51-200 employees
+ Follow
Message
Home
About
Posts
Jobs
People
1 associated member
Search employees by title, keyword or s
Los Angeles, CA
Clear all
Where they live
+ Add
Where they studied
1 | Guangdong Universit


5 | Changsha
Bonerge Lifescience
Home
About
Posts
Jobs
People
5 | Changsha-Zhuzhou-Xiangtan Metropolitan ...
1 | California, United States
1 | Los Angeles, CA
1 | United States
1 | Los Angeles Metropolitan Area
Show less
People you may know
chen Jack · 3rd
Bonerge- Sales Manager

Bonerge Lifescience

Home About Posts Jobs People



Pages people also viewed

Zhejiang Junyi Laser Equipment Co.,Ltd.
Industrial Machinery Manufacturing
4 followers
+ Follow

Herbal Clinician™
Public Health
1 follower
+ Follow

Huiyao Laser Technology(Luoyang) Co.,Ltd
Renewable Energy Equipment Manufacturing
34 followers
+ Follow

Show all →

Bonerge Lifescience

Home About Posts Jobs **People**

26,225 followers

+ Follow

Sheppard Mullin Richter & Hampton LLP
Law Practice
22,308 followers

John Keville & 3 other connections work here

+ Follow

Japan Patent Office
Government Administration
3,181 followers

Navin follows this page

+ Follow

Show all →





About Accessibility Help Center

Bonerge Lifescience

Home About Posts Jobs **People**

EXHIBIT 7





chen Jack · 3rd

Bonerge- Sales Manager

- Bonerge Lifescience
- 广东外语外贸大学南国商学院

Los Angeles, California, United States · Contact info

431 connections

Message + Follow More

Activity

436 followers

Posts Comments Images

chen Jack posted this • 4mo

The importance of Equol?
Non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated steatohepatopathy (MASLD) is defined as the accumulation c ...show more

chen Jack posted this • 4mo

What is Equal?
... ...show more

Quality,Safety and Love of Life

bonerge.com

chen Jack posted this • 5mo

The source of Fisetin
... ...show more

Quality,Safety and Love of Life

bonerge.com

Show all posts →

Experience

Sales Professional

Bonerge Lifescience

Jul 2024 - Present · 7 mos

On-site

销售

Ragos NC equipment co.,LTD
Full-time · 7 yrs 10 mos
中国 广东省 佛山市 · On-site

国际销售总监
Jan 2019 - Present · 6 yrs 1 mo

国际销售, 直销 and +3 skills

General Sales Manager
Apr 2017 - Present · 7 yrs 10 mos

Education

Guangdong University of Foreign Studies South China Business College
学士学位, 商务英语
Sep 2016 - Jun 2020

Skills

销售

Sales Professional at Bonerge Lifescience

销售工程师

国际销售总监 at Ragos NC equipment co.,LTD

Show all 6 skills →

Interests

Companies | Newsletters | Schools

Flowserve Corporation
342,208 followers
+ Follow

TRUMPF North America
42,283 followers
+ Follow

Show all companies →

Promoted •••

Knovos

Knovos

Mark, you might like to follow Knovos

Stay informed on industry news and trends

Follow

More profiles for you



Mia N. · 3rd
Looking for distributor/international partner/dealers! Fiber laser cutting machine/Fiber laser cutter

View profile



Annie Best · 3rd
Sales Director for the UK Market,Jinan Bodor CNC Machine Co.,Ltd.

+ Follow



John O'Neal NC Stargazer · 3rd
NC Stargazer

View profile



Halina Hu · 3rd
Sales manager

View profile



Anne Zhang · 3rd+
济南马伯卡机械有限公司 - 销售业务员

Message

Show all

Explore Premium profiles



Earl Yang · 3rd+
Student at University of Southern California

Message



Brian Franklin · 2nd
Partner at Gartner + Bloom PC in Manhattan, New York. Licensed in NY, CA, FL, FA, NJ and AZ, with experience in products liability, construction, gener...

Connect



Christopher Lekawa · 2nd
Corporate and M&A Partner | Commercial Real Estate Transactions | Grant, Genovese & Baratta, LLP

Connect



Chris LaVigne · 2nd
Shareholder @ Greenberg Traurig | Licensed in Texas, Federal Courts

Connect

People you may know



Glen Starr, CFP®
Working with individuals and business owners to create "life" financial plans designed to weather inflation and sustain you throughout retirement...

Connect



Haley Jones
Attorney

Connect



Rebecca Van Hooser
Litigation Paralegal @ BURT BARR & ASSOCIATES, L.L.P. | Trial preparation, insurance defense & plaintiff claims

Connect



Abbye West
Associate Attorney at Scheef & Stone

Connect



Dan Tobin
Eminent Domain & Condemnation Attorney | Standing up for landowners. Standing up to government.

Connect

Show all

You might like
Pages for you

RMO LLP
Legal Services
3,008 followers



2 connections work here

+ Follow

Sheppard Mullin Richter & Hampton LLP
Law Practice
22,308 followers



4 connections work here

+ Follow

Show all

EXHIBIT 8

businesswire
A BERKSHIRE HATHAWAY COMPANY

Bonerge Initiates the Human Clinical Trail Plans for GlucoSober®-Dihydroberberine and BeFisetin®-Fisetin

July 31, 2024 02:40 PM Eastern Daylight Time

NEW YORK--(BUSINESS WIRE)--Bonerge is excited to announce the initiation of clinical trials for its high-quality brand ingredients, including GlucoSober and BeFisetin. These trials aim to substantiate the efficacy and safety of the products, providing more reliable options for the market.

In an era where health consciousness is on the rise, consumers are increasingly seeking high-quality dietary supplements. Bonerge is embarking on several clinical trials to make evidence-based ingredients that meet the needs of consumers.

Key Products Undergoing Clinical Trials

BeFisetin®: This high-quality Fisetin with total flavonoids greater than 99%, Fisetin content greater than 98% and impurity smaller than 1%. Previous preclinical studies have shown that fisetin can effectively clear senescent cells, targeting one of the hallmarks of aging. [1,2] The upcoming clinical trials will further investigate BeFisetin's potential benefits to support the market.

GlucoSober®: An ultra-pure Dihydroberberine with stable quality, GlucoSober is a derivative of the popular weight-loss supplement Berberine. While Berberine has a bioavailability of less than 1%, Dihydroberberine has shown more effective. [3] As an ultrapure product, higher purity means more active ingredients that are packed. GlucoSober is set to be the product to undergo human clinical trials to validate the benefits of Dihydroberberine.

Additionally, Bonerge will conduct clinical research on product formulations to investigate the synergistic effects of ingredients to meet personalized demand. Further details will be announced.

The Initiates of Choosing Clinical Trials

Exploring the functions and applications of ingredients requires collaboration among scientists, manufacturers, and brands. As the mainstream Dihydroberberine supplier, Bonerge continues to explore scientifically proven health longevity and metabolic health ingredients. Bonerge partners with leading brands to ensure consumers have access to high-quality products that help them to maintain a balanced blood glucose level.

About Bonerge

Bonerge is one innovative team and lab specialized in longevity and metabolic health ingredients. Bonerge closely follow up on the latest anti-aging science, develop novel longevity ingredients. Bonerge is guided by 12 hallmarks of aging. Live longer and healthier.

References

1. Yousefzadeh, Matthew J et al. “Fisetin is a senotherapeutic that extends health and lifespan.” *EBioMedicine* vol. 36 (2018): 18-28. doi:10.1016/j.ebiom.2018.09.015


2. López-Otín, Carlos et al. “Hallmarks of aging: An expanding universe.” *Cell* vol. 186,2 (2023): 243-278. doi:10.1016/j.cell.2022.11.001

3. Xu, Hong-Yu et al. “Nanoemulsion improves hypoglycemic efficacy of berberine by overcoming its gastrointestinal challenge.” *Colloids and surfaces. B, Biointerfaces* vol. 181 (2019): 927-934. doi:10.1016/j.colsurfb.2019.06.006

Contacts

Cecilia Yang
+1 (949) 712-7328
sales@bonerge.com

EXHIBIT 9



+1 (949) 712-7328

sales@bonerge.com

Bonerge Inc

2049 S. Hellman Ave, Unit A, Ontario, CA 91761, USA

R&D Center

Bonerge Lifescience(Hunan) Co., Ltd.

Add: Room 102, building 7, Depu Wuhe Enterprise Park, Changsha City, Hunan, China

Let's Work Together

First Name

Last Name

Email

Phone

Comany

City

Your Message

NNB Exh. 2147, p. 063

BONERG

Bontanical Energy for Healthy Aging Quality,Safety and Love of Life

Quick Links

About Us
BongeLov System
News & Articles
BeFisetin

Our Products

Branded Ingredients
Featured Ingredients
Classic Ingredients

Disclaimer: All health claims are based on scientific research and are not intended to diagnose, cure or prevent any disease.

Contact Info

2049 S. Hellman Ave, Unit A, Ontario CA 91761, USA

+1 (949) 712-7328

sales@bonerge.co

Join us

EXHIBIT 10



(12) **United States Patent**
Lowery et al.

(10) **Patent No.: US 10,278,961 B2**
(45) **Date of Patent: May 7, 2019**

(54) **ADMINISTRATION OF BERBERINE METABOLITES**

(71) Applicant: **Keto Patent Group, Inc.**, Melissa, TX (US)

(72) Inventors: **Ryan Lowery**, Tampa, FL (US); **Jacob Wilson**, Tampa, FL (US); **Shawn Wells**, Lewisville, TX (US); **Terry LaCore**, Melissa, TX (US)

(73) Assignee: **Keto Patent Group, Inc.**, Melissa, TX (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **15/491,933**

(22) Filed: **Apr. 19, 2017**

(65) **Prior Publication Data**

US 2017/0296520 A1 Oct. 19, 2017

Related U.S. Application Data

(60) Provisional application No. 62/324,794, filed on Apr. 19, 2016.

(51) **Int. Cl.**

A61K 31/4355	(2006.01)
A61K 9/00	(2006.01)
A61K 38/00	(2006.01)
A61K 47/54	(2017.01)
A61K 9/107	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 31/4355*** (2013.01); ***A61K 9/0095*** (2013.01); ***A61K 38/005*** (2013.01); ***A61K 47/544*** (2017.08); *A61K 9/1075* (2013.01)

(58) **Field of Classification Search**

CPC C07D 455/03; A61K 314/4355

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2010/0113494	A1 *	5/2010	Hu	C07D 455/03 514/280
2014/0350105	A1	11/2014	D'Agostino et al.	
2015/0063140	A1	3/2015	Yi et al.	

OTHER PUBLICATIONS

International Search Report and Written Opinion for PCT/US17/28466 dated Jul. 5, 2017 (9 pages).

* cited by examiner

Primary Examiner — Paul V Ward

(74) *Attorney, Agent, or Firm* — Ferguson Braswell Fraser Kubasta PC; Elizabeth Philip Dahm; Kelly J. Kubasta

(57) **ABSTRACT**

In various implementations, berberine metabolites, such as dihydroberberine and/or tetrahydroberberine, may be administered to manage blood glucose levels, increase ketone levels (e.g., blood concentration of ketones), and/or for therapeutic purposes in humans. The administration of a pharmaceutically effective amount of berberine metabolites, such as dihydroberberine, may reduce fasting blood glucose levels, improve glucose tolerance, and/or improve blood ketone response. In some implementations, berberine metabolites may be administered with one or more other compounds.

20 Claims, 4 Drawing Sheets

Case 5:25-cv-00271 Document 1-1 Filed 01/31/25 Page 52 of 139 Page ID #:67





Figure 1



Subject 1		Subject 2		Subject 3		Subject 4		Subject 5	
1	500 mg DHBB	1	250 mg DHBB	1	250 mg DHBB	1	500 mg DHBB	1	500 mg DHBB
2	250 mg DHBB	2	500 mg DHBB	2	500 mg DHBB	2	250 mg DHBB	2	500 mg BB HCL
3	500 mg BB HCL	3	500 mg BB HCL	3	500 mg BB HCL	3	500 mg BB HCL	3	250 mg DHBB

Figure 2

Case 5:25-cv-00271 Document 1-1 Filed 01/31/25 Page 54 of 139 Page ID #:69




Figure 3

Figure 4

Subject	Condition	Baseline	30 minutes	60 minutes	90 minutes	120 mintues	180 minutes
1	500 mg Berb HCL	83	142	121	108	93	88
2	500 mg Berb HCL	90	113	88	112	131	83
3	500 mg Berb HCL	103	103	149	96	83	80
4	500 mg Berb HCL	96	96	97	101	102	87
5	500 mg Berb HCL	88	88	133	104	81	80
Average		92	92	117.6	104.2	98	83.6
1	500 mh Dihydro	76	97	117	98	97	96
2	500 mh Dihydro	74	109	106	101	96	92
3	500 mh Dihydro	93	131	102	102	102	113
4	500 mh Dihydro	81	102	119	94	90	84
Average		81	110	111	98.75	96.25	96.25
1	250 mh Dihydro	88	139	116	114	100	94
2	250 mh Dihydro	92	93	102	114	96	88
3	250 mh Dihydro	108	133	104	103	101	103
4	250 mh Dihydro	77	116	105	100	104	97
5	250 mh Dihydro	91	130	92	95	88	88
Average		91.2	122.2	103.8	105.2	97.8	94

ADMINISTRATION OF BERBERINE METABOLITES

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Patent Application No. 62/324,794, entitled "ADMINISTRATION OF DIHYDROBERBERINE", filed on Apr. 19, 2016, which is incorporated by reference for all purposes.

TECHNICAL FIELD

The present invention relates to managing metabolic and therapeutic functions by administering berberine metabolites.

BACKGROUND

Berberine is a naturally occurring substance commonly found in Goldenseal (*Hydrastis canadensis*), Oregon grape (*Berberis aquifolium*), Barberry (*Berberis vulgaris*), Chinese Goldthread (*Coptis chinensis, Phellodendron chinense*, and *Phellodendron amurense*. Berberine has been administered to humans and found to have an effect on inflammation and as well as having some antimicrobial properties. Berberine has also shown potential for lowering fasting blood glucose; however adverse gastrointestinal effects appeared to accompany the administration in amounts to effectively lower fasting blood glucose (Yin et al. "Efficacy of Berberine in Patients with Type 2 Diabetes," Metabolism. 2008 May; 57(5): 712-717). The bioavailability of traditional berberine has been shown in some studies to be below 70% in animal models which could affect how much is being absorbed and actually utilized in the body (Chen, W., Miao, Y. Q., Fan, D. J., Yang, S. S., Lin, X., Meng, L. K., & Tang, X. (2011). Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats. Aaps Pharmscitech, 12(2), 705-711.)

SUMMARY

In various implementations, one or more berberine metabolites (e.g., dihydroberberine and/or tetrahydroberberine) may be administered to manage glucose tolerance and/or increase ketones (e.g., blood concentration and/or urine concentration of ketones) in humans. For example, a pharmaceutically effective amount of berberine metabolites (e.g., dihydroberberine and/or tetrahydroberberine) may be administered to healthy and/or nonhealthy adults. For example a pharmaceutically effective amount of berberine metabolites may be administered to a human with diabetes or other metabolic disorder impacting glucose tolerance. The berberine metabolites may regulate glucose and/or lipid metabolism. In some implementations, administration of a pharmaceutically effective amount of berberine metabolites may be therapeutic to humans with diabetes, glucose intolerance, metabolic syndrome, dyslipidemia, and/or obesity/overweight. In some implementations, administration of berberine metabolites may have ergogenic (e.g., performance enhancing) and/or body composition benefits for some individuals (e.g., generally healthy; athletic; etc.) via glucose disposal, insulin sensitivity and ketone sensitivity. In some implementations, administration of berberine metabolite(s) may lower glycation (e.g., measured by HA1c levels) which may provide anti-aging properties.

In various implementations, the berberine metabolite composition administered to an individual may include dihydroberberine and/or tetrahydroberberine. For example, the composition may be orally administered in any appropriate delivery vehicle, such as via tablets, capsules, food products, and/or beverage products.

In some implementations, one or more berberine metabolites may be administered with one or more additional compounds. The additional compounds, such as ketone sensitizers, may be capable of independently inducing ketosis. The additional compounds may be utilized to maintain and/or promote ketosis in humans. For example, the additional compounds may include one beta-hydroxybutyrate compound; butyrate; short chain, medium chain, and/or long chain fatty acids or esters thereof; and/or combinations there of which may be administered with a berberine metabolite, such as dihydroberberine.

In various implementations, a pharmaceutically effective amount of dihydroberberine may be administered to an individual to managing glucose tolerance (e.g., decrease and/or maintain blood glucose level, decrease and/or maintain fasting blood glucose, increase ability to process glucose, etc.).

Implementations may include one or more of the following features. The administration of dihydroberberine may reduce fasting glucose levels. The dihydroberberine may be administered as a complexed composition. The complexed composition may include phytosomes and/or liposomes. The dihydroberberine may be a microemulsion including dihydroberberine. The pharmaceutically effective amount of dihydroberberine may include approximately 25 mg to approximately 800 mg of dihydroberberine, in some implementations. The dihydroberberine may be orally administered as a capsule, tablet, a food product, and/or beverage product. The dihydroberberine may be administered at least once daily (e.g., for a period of time, when desired by the user, etc.). In some implementations, a Cytochrome P450 inhibitor may be administered approximately concurrently. Administration of the Cyctochrome P450 inhibitor may allow decreasing of the amount of dihydroberberine administered to be sufficient to achieve the desired results (e.g., the same level of glucose management as a predetermined amount of dihydroberberine, a normal range of fasting glucose levels per health guidelines, normal level of blood glucose level per health guidelines, etc.).

In various implementations, administering, to an individual, a pharmaceutically effective amount of dihydroberberine may increase blood ketone levels.

Implementations may include one or more of the following features. The dihydroberberine may be administered approximately concurrently with meals. In some implementations, a pharmaceutically effective amount of an additional compound may be administered with the dihydroberberine, where the additional compound is capable of inducing ketosis independently (e.g., ketone sensitizer). The dihydroberberine and additional compound may be administered approximately concurrently. The dihydroberberine and additional compound may be administered at least one time daily (e.g., for a period of time, per user desire, per doctor recommendation, until glucose level and/or blood ketone level is within a predetermined range, etc.).

In various implementations, composition may be capable of maintaining ketosis in an individual (e.g., within a predetermined time period of administration to the individual). The composition may include a pharmaceutically effective amount of dihydroberberine and an additional compound (e.g., a compound that can impact blood ketone levels

independently, such as a ketone sensitizer). The amount of dihydroberberine administered to be pharmaceutically effective may be less than the amount of dihydroberberine administered to be pharmaceutically effective when the dihydroberberine is administered without the additional compound(s) (e.g., to achieve a predetermined level of ketosis and/or a range of blood ketone levels).

Implementations may include one or more of the following features. The additional compound(s) may include beta-hydroxybutyrate (e.g., R-beta-hydroxybutyrate and/or D,L-beta-hydroxybutyrate), butyrate, fatty acid, and/or ester of fatty acid. The additional compound may include R-beta-hydroxybutyrate (e.g., salt, polymer, and/or complexed with another compound such as an amino acid). The additional compound may include a beta-hydroxybutyrate salt, beta-hydroxybutyrate polymer, beta-hydroxybutyrate amino acid (e.g., R-beta-hydroxybutyrate amino acid mixture and/or complex, such as R-beta-hydroxybutyrate and leucine), and/or beta-hydroxybutyrate free acid(s). The dihydroberberine and additional compound may be administered approximately concurrently. The dihydroberberine and additional compound may be a mixture and/or a complexed compound. The additional compound may include a beta-hydroxybutyrate and at least one of a fatty acid or ester of a fatty acid, in some implementations.

The details of one or more implementations are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the implementations will be apparent from the description and drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

For a more complete understanding of this disclosure and its features, reference is now made to the following description, taken in conjunction with the accompanying drawings, in which:

FIG. **1** illustrates table with glucose levels for subjects after administration of an example administration protocol.

FIG. **2** illustrates a table of subject responsiveness to an example administration protocol.

FIG. **3** illustrates a table with blood ketone levels for subjects after administration of an example administration protocol.

FIG. **4** a table with blood ketone levels for subjects after administration of an example administration protocol.

Like reference symbols in the various drawings indicate like elements.

DETAILED DESCRIPTION

In various implementations, administration of a pharmaceutically effective amount of berberine metabolites (e.g., dihydroberberine and/or tetrahydroberberine), derivates thereof and/or salts thereof may be administered to humans to manage blood glucose levels (e.g., reduce fasting blood glucose, improve glucose tolerance, etc.). In some implementations, administration of pharmaceutically effective amount of berberine metabolite(s) may maintain and/or increase ketone levels (e.g., blood and/or urine ketone concentration). In some implementations, administration of a pharmaceutically effective amount of berberine metabolite(s) (e.g., dihydroberberine and/or tetrahydroberberine) may be therapeutic to humans with diabetes, glucose intolerance, metabolic syndrome, dyslipidemia, and/or obesity/overweight. In some implementations, administration of berberine metabolites may have ergogenic (e.g., performance enhancing) and/or body composition benefits for some individuals (e.g., generally healthy; athletic; etc.) via glucose disposal, insulin sensitivity and ketone sensitivity. In some implementations, administration of a pharmaceutically effective amount of berberine metabolite(s) may lower glycation (e.g., measured by HA1c levels) which may provide anti-aging properties. The amount of berberine metabolite (e.g., dihydroberberine) administered to achieve a predetermined effect (e.g., fasting blood glucose level) may be less than the amount of berberine that would be required to achieve the same predetermined effect. In some implementations, one or more other compounds may be administered with the pharmaceutically effective amount of berberine metabolite, such as a ketone sensitizer (e.g., a compound that is capable of reducing and/or maintaining blood ketone levels independently, such as beta-hydroxybutyrate, short chain fatty acids, medium chain fatty acids, and/or long chain fatty acids).

In some implementations, a berberine metabolite composition may include dihydroberberine and/or tetrahydroberberine. Dihydroberberine ($C_{20}H_{19}NO_4$) is a compound that although related to berberine has properties that make it especially suited for managing glucose and/or increasing ketone levels (e.g., blood ketone levels). Dihydroberberine is a compound that is commercially available from sources such as, AdooQ Bioscience (Irving, Calif.).

Dihydroberberine may be more biologically available to humans than berberine. A first weight amount of dihydroberberine is capable of decreasing blood glucose levels greater than the same weight amount of berberine. A first weight amount of dihydroberberine may increase blood ketone levels more than the same weight amount of berberine. These are unexpected results since the inclusion of other function groups (hydro-) decreases the amount of "berberine" in the same weight amount of berberine. By increasing blood ketone levels, achieving a level of ketosis (e.g., blood ketone levels of 0.2 to 20 mM), maintaining a level of ketosis may be more easily obtainable during administration of dihydroberberine. Achieving ketosis may improve metabolic disorders, improve health (e.g., strength, mental acuity, etc.), increase weight loss, and/or increase fat loss (e.g., as opposed to lean muscle mass loss). Diabetes, various types of cancer, Alzheimer's, Parkinson's, Traumatic Brain Injury (TBI) PCOS, Metabolic Syndrome/Syndrome X, Obesity, Dyslipidemia, Aging, other metabolic disorders and/or other ketosensitive diseases and/or disorders may thus be affected by administration of dihydroberberine or tetrahydroberberine (e.g., since ketosis may be more easily achieved by individuals in which dihydroberberine has been administered).

In various implementations, the berberine metabolite may include tetrahydroberberine ($C_{20}H_{21}O_4N$). Tetrahydroberberine is a compound that although related to berberine has properties that make it especially suited for managing glucose and/or increasing ketone levels (e.g., blood ketone concentration). In some implementations, dihydroberberine and/or tetrahydroberberine may be complexed with other compounds such as phytosomes and/or liposomes. The berberine metabolite may be administered to a user via the complexed compound.

In various implementations, a pharmaceutically effective amount of berberine metabolite may be administered to humans to improve glucose tolerance. For example, an amount of approximately 25 mg to approximately 800 mg of dihydroberberine may be administered to a human. In some implementations, an amount of approximately 250 mg to approximately 300 mg may be administered to a human. The amount of dihydroberberine may be less than the amount of

berberine required to achieve the same amount of glucose tolerance (e.g., a predetermined fasting glucose level, a predetermined range of blood glucose, a normal or other blood glucose level as determined by health guidelines, a normal or other fasting blood glucose as determined by health guidelines, etc.). In some implementations, an amount of dihydroberberine may provide the same level of glucose tolerance as at least double the same amount of berberine (e.g., the dihydroberberine may be at least twice as effective as berberine and thus half or less than half of a first amount of dihydroberberine would be required to achieve the same results as the first amount of berberine). This result is unexpected since one would expect berberine and dihydroberberine to have similar properties. Even with the known increase bioavailability of dihydroberberine over berberine, the ability to administer as little as half as much dihydroberberine as berberine to achieve similar results in glucose tolerance is unexpected. The ability to reduce the quantity of dihydroberberine administered to a human may reduce the side effects associated with administration, ease palatability (e.g., since taste may improve or be more easily masked with smaller dosages), ease administration (e.g., smaller dose size), reduce costs, etc. For example, since the same amount (e.g., molecular amount) of the "berberine" group is in berberine and dihydroberberine, decreasing the amount administered would decrease side effects associated with administration of berberine and/or related complexes.

In various implementations, one or more additional compounds may be administered with the berberine metabolite. The additional compounds may increase a benefit of the berberine metabolite (e.g., glucose management, decrease ketone levels, etc.) and/or provide additional benefits (e.g., increase mental acuity, increase fat loss, increase lean mass maintenance, increase strength, etc.) For example, an additional compound that is capable of impacting blood ketone levels (e.g., increasing and/or maintaining blood ketone levels, inducing ketosis, etc.), such as a ketone sensitizer, may be selected that increases ketosis (e.g., increase levels of ketones bodies in the blood).

In some implementations, the additional compounds (e.g., ketone sensitizers) may include a beta-hydroxybutyrate compound may be administered with the berberine metabolite (e.g., in a capsule such as a softgel; tablet; powdered supplement; ready-to-drink formulation; topical product; cosmeceutical product; foods such bars, cookies, gum, candy, functional foods; toothpaste, sublingual product; injection; intravenous fluids; beverages such as shots or energy shots; inhalers and/or other appropriate administration methods). A beta-hydroxybutyrate compound may include beta-hydroxybutyrate salts, beta-hydroxybutyrate monomer, beta-hydroxybutyrate polymers, and/or combinations thereof. For example, beta-hydroxybutyrate salts may include sodium beta-hydroxybutyrate, magnesium beta-hydroxybutyrate, calcium beta-hydroxybutyrate, lithium beta-hydroxybutyrate, potassium beta-hydroxybutyrate and/or combinations thereof. In some implementations, beta-hydroxybutyrate polymers may be selected for administration with dihydroberberine to administer beta-hydroxybutyrate (e.g., since beta-hydroxybutyrate polymers are metabolized in the body to administer beta-hydroxybutyrate). In some implementations, the beta-hydroxybutyrate administered may include organic salts, such as but not limited to, arginine beta-hydroxybutyrate, lysine beta-hydroxybutyrate, histidine beta-hydroxybutyrate, ornithine beta-hydroxybutyrate, creatine beta-hydroxybutyrate, agmatine beta-hydroxybutyrate, citrulline beta-hydroxybutyrate, and/or combinations thereof. The beta-hydroxybutyrate included in the composition may include R-beta-hydroxybutyrate (e.g., salts, polymers, complexes, etc.). The beta-hydroxybutyrate may include single isomer R-beta-hydroxybutyrate and/or polymer R-beta-hydroxybutyrate. In some implementations, beta-hydroxybutyrate may be administered with 1,3-butanediol, ethyl acetoacetate, ethyl beta-hydroxybutyrate.

In some implementations, the additional compound (e.g., that is capable of increasing blood ketone levels independently) may include a fatty acid and/or ester thereof. For example, the additional compound may include short chain, medium chain, and/or long chain fatty acids and/or esters thereof. The fatty acid(s) and/or esters thereof may include natural and/or synthesized compounds. For example, the additional compound may include coconut oil, butter, etc.

In some implementations, the composition may include more than one additional compound that is capable of increasing blood ketone levels and/or inducing ketosis independently (e.g., without dihydroberberine). For example, a medium chain fatty acid may be administered with the berberine metabolite and/or beta-hydroxybutyrate compound. In some implementations, an amino acid may be administered with dihydroberberine and R-beta-hydroxybutyrate (e.g., salt, polymer, and/or complex).

In various implementations, a composition may be administered as described that includes berberine metabolites (e.g., Dihydroberberine, tetrahydroberberine, etc.) and/or an additional compound that increases ketone levels (e.g., blood and/or urine), such as a ketone sensitizer. The additional compound(s) may include one or more beta-hydroxybutyrate compounds, short chain triglycerides, medium chain triglycerides, long chain triglycerides, combinations thereof and/or derivatives thereof. For example, one or more of the beta-hydroxybutyrate compounds and/or other ketone sensitizers (e.g., short chain triglycerides, medium chain triglycerides, long chain triglycerides) in U.S. patent application Ser. No. 15/491,924, to Lowery et al. and entitled "Administration of Beta-hydroxybutyrate and Related Compounds in Humans", filed Apr. 19, 2017 and U.S. Provisional Patent Application No. 62/324,798, to Lowery et al. and entitled "Administration of Beta-hydroxybutyrate and Related Compounds in Humans", filed Apr. 19, 2016, which is incorporated by reference to the extent that the teachings do not conflict with the present disclosure, may be utilized as a ketone sensitizer.

To achieve a predetermined amount of ketosis in an individual, an amount of an additional compound (e.g., capable of increasing ketone levels and/or inducing ketosis independently) administered with berberine metabolite(s) (e.g., Dihydroberberine, tetrahydroberberine, etc.) may be less than an amount of the additional compound administered without dihydroberberine. In some implementations, when berberine metabolite(s) (e.g., Dihydroberberine, tetrahydroberberine, etc.) is administered, as blood glucose levels decrease, unexpectedly, blood ketone levels may rise. Thus, less of the additional compound may be administered to achieve a predetermined blood ketone level (e.g., to maintain and/or promote a state of ketosis). For example, an additional compound, such as 10 grams of sodium beta-hydroxybutyrate may be administered to a 200 pound human to achieve a first level of ketosis (e.g., blood ketone level of 0.5 mM). When dihydroberberine is administered, the amount of the additional compound may be decreased. For example, when 250 mg of dihydroberberine is administered to a 200 pound human, 3 milligrams of sodium beta-hydroxybutyrate may be administered to achieve the first level of ketosis rather than 10 grams of sodium beta-hydroxybutyrate. Administration of the additional com-

pound (e.g., that is capable of independently increasing ketone levels and/or inducing ketosis) may cause increase user satisfaction (e.g., less side effects from increased amounts of the additional compound and/or cation when salts of the additional compounds are included) and/or decreases costs (e.g., since less of the additional compound may be utilized), and enhance endogenous production (e.g. since blood glucose is lower, endogenous ketones may be elevated alongside the exogenous ketones)

In some implementations, the berberine metabolite(s) (e.g., dihydroberberine tetrahydroberberine, etc.) and the additional compound (e.g., capable of increasing ketone levels in the blood) may be administered approximately concurrently. For example, the dihydroberberine and ketone sensitizer may be provided in a capsule, pill, granular form (e.g., packet of granules), powdered form, liquid, gel, sublingual, transdermal and/or any other appropriate administration form.

In some implementations, one or more additives may be included in the composition, such as flavorings (e.g., natural and/or artificial), vitamins, minerals, binders, and/or any other appropriate additive. The additives may alter flavor, color, and/or texture. The additives may increase palatability and/or facilitate inclusion in a delivery vehicle (e.g., tablet, food product, beverage product such as a drink mix, etc.).

In some implementations, the berberine metabolite(s) may be processed to increase bioavailability, solubility, palatability, and/or combination with other compounds. For example, berberine metabolite(s) may be processed to form a microemulsion with other compounds (e.g., ketone sensitizer, liposome, phytosome, flavorings, etc.). In some implementations, the berberine metabolite may be microencapsulated (e.g., with and/or without other compounds such as ketone sensitizer, liposome, phytosome). Microemulsions may improve bioavailability and solubility as well as other agglomeration technologies. The microencapsulated berberine metabolite(s) (e.g., with or without combination with other compounds) may be a free flowing granular powder; dispersible in water; stable in acidic water solution for 30 minutes; allow controlled release in stomach and/or small intestines; inhibit glucose response (e.g., to any added materials); and/or allow delivery of a high butyrate content (e.g., around 70%), in some implementations. In some implementations, the berberine metabolite may be complexed with another compound (e.g., liposome, phytosome, and/or combinations thereof) and the berberine metabolite complex may be administered to the user to administer the berberine metabolite. Bioavailability enhancement via the mechanism of action for Cytochrome P450 inhibitors like naringen, bergamotin, piperine and its metabolites, as well as other bioavailability enhancers may be co-administered to enhance efficacy at lower therapeutic doses. Lowering the therapeutic dosage may decrease side effects and/or costs.

In various implementations, the berberine metabolite(s) (e.g., Dihydroberberine, tetrahydroberberine, etc.) and/or other compounds administered with the dihydroberberine may be administered on an appropriate administration schedule. For example, the Dihydroberberine/tetrahydroberberine and/or other compounds may be administered concurrently with meals, a predetermined amount of time before meals, a predetermined amount of time after meals, at regular or irregular time intervals, and/or according to other appropriate administration schedules. The berberine metabolite composition (e.g., including the berberine metabolite) may be administered on a periodic basis and/or as desired by a user. For example, the berberine metabolite composition may be administered to achieve a predetermined blood glucose level and/or fasting level. The administration of the composition (e.g., in the same and/or lower dosage) may be continued and/or discontinued once the predetermined level is achieved. The berberine metabolite composition may be administered as desired by a user in some implementations (e.g., to facilitate achieving user goals such as in strength training, for performance, for insurance testing, etc.). In some implementations, the amount of Dihydroberberine/tetrahydroberberine and/or other compounds administered at each dose may be the same and/or different.

In some implementations, the composition administered to an individual (e.g., human and/or any other appropriate animal) may include approximately 5 mg to approximately 1 gram of dihydroberberine. The composition may include one or more other compounds that may or may not be capable of increasing blood ketone levels independently, in some implementations. The composition may be administered (e.g., orally) approximately 1 to approximately 3 times daily. In some implementations, the composition may be provided in a delivery form such powder (e.g., that capable consumed separately, mixed with drinks, and/or food) and/or tablet. The administration of the composition may maintain ketosis levels for approximately 30 min to approximately 3 hours. The administration of the composition may maintain ketosis for longer than 3 hours. The administration of the composition may maintain blood glucose levels within a healthy range (e.g., as determined by a doctor, health guidelines, insurance guidelines, etc.). The administration of the composition may decreases blood glucose levels during a glucose challenge testing by over 25%, in some implementations. The administration of the composition may be capable of maintaining approximately 2 to approximately 3 times greater elevated ketones during carbohydrate intake (e.g., when compared with berberine and/or when compared with individuals not being administered dihydroberberine). The administration of the composition may increased fat metabolism by 10% (e.g., when compared with the individuals capability without administration of dihydroberberine).

In some implementations, the compound may include dihydroberberine and a beta-hydroxybutyrate. The composition may include one or more other compounds that may or may not be capable of increasing blood ketone levels independently, in some implementations. The composition may include approximately 5 mg to approximately 1 g of dihydroberberine and approximately 2 g of beta-hydroxybutyrate to approximately 10 g of beta-hydroxybutyrate. In some implementations, the composition may include approximately 400 mg to approximately 600 mg of dihydroberberine (e.g., approximately 500 mg) and approximately 4 to approximately 7 g of beta-hydroxybutyrate (e.g., 5 g of beta-hydroxybutyrate, such as R-beta-hydroxybutyrate). The composition may be administered (e.g., orally) approximately 1 to approximately 3 times daily. In some implementations, the composition may be provided in a delivery form such powder (e.g., that capable consumed separately, mixed with drinks, and/or food) and/or tablet. The combination of dihydroberberine and additional compounds that are capable of increasing ketones independently, such as beta-hydroxybutyrate, may increase ketones at a greater level than the expected additive amount. For example, a composition of 500 mg of dihydroberberine and 5 grams of beta-hydroxybutyrate and 5 grams of short chain triglyceride may increase ketones over 1 mM (e.g., while 5 grams of BHB alone elevate blood ketone levels to only 0.5 mM)

In some implementations, the dihydroberberine may be complexed or otherwise coupled to one or more of the additional compounds in the composition. For example, the composition may include a dihydroberberine-betahydroxybutyrate complex and/or a dihydroberberine-amino acid complex.

EXAMPLE

Example 1

Five subjects were subject to three separate glucose challenge tests (75 g glucose) after administration of 500 mg berberine (BB), 250 mg of dihydroberberine (DHBB) or 500 dihydroberberine. Blood was drawn prior to administration and after 30, 60, 90, 120, and 180 minutes. FIG. **1** illustrates the results of the administration protocol. FIG. **1** illustrates the average blood glucose level of the 5 subjects at each of the times.

As illustrated, unexpectedly, administration of the dihydroberberine resulted in less fluctuations in blood glucose level than berberine. In addition, an unexpected result of the administration of dihydroberberine is that administration of dihydroberberine may keep blood glucose levels closer to fasting blood glucose than berberine.

Example 2

As in Example 1, five subjects were subject to three separate glucose challenge tests (75 g glucose) after administration of 500 mg berberine (BB), 250 mg of dihydroberberine (DHBB) or 500 dihydroberberine. FIG. **2** illustrates a ranking which compositions caused the lowest blood glucose levels during a oral glucose challenge. Unexpectedly, 250 mg of DHBB may control blood glucose levels better than even 500 mg of DHBB. For example, in some individuals (e.g., individuals with moderate glucose tolerance) may achieve better blood glucose control when administered a lower dosage of DHBB. As illustrated, dihydroberberine administration resulted in lower blood glucose than administration of berberine in most individuals.

Example 3

A subject was subject to a glucose challenge test (75 g glucose) after administration of 250 mg dihydroberberine (DHBB) and a glucose challenge test after administration of 250 mg dihydroberberine (DHBB) along with 5 mg of beta-hydroxybutyrate (e.g., 5 mg sodium beta-hydroxybutyrate). As illustrated in FIG. **3**, blood ketone levels are unexpectedly increased even 120 minutes after the glucose challenge with the administration of an effective amount of dihydroberberine.

Example 4

Five subjects were subject to three separate glucose challenge tests (75 g glucose) approximately 25 minutes after administration of 500 mg berberine (BB), 250 mg of dihydroberberine (DHBB) or 500 dihydroberberine. Blood was drawn prior to administration and after 30, 60, 90, 120, and 180 minutes and tested for glucose levels. FIG. **4** illustrates the results of the administration protocol.

As illustrated, administration of dihyroberberine in individuals with moderate baseline glucose levels moderates blood glucose levels better than even double the quantity of berberine.

End of Example

The described compositions may be administered via any appropriate administration method. For example, the described compositions may be administered enterally and/or parenterally. In some implementations, the described composition may be administered via a tablet and/or capsule. In some implementations, the described composition may be administered via tablet, capsule, powdered supplement; ready-to-drink formulation; topical product including transdermals; cosmeceutical product; foods such bars, cookies, gum, candy, functional foods; toothpaste, sublingual product; injection; intravenous fluids; beverages such as shots or energy shots; inhalers; sublinguals; and/or combinations thereof. The described composition may be provided in a powdered form that allows the described composition to be sprinkled on food, mixed with a liquid to provide a beverage, directly administered.

The described compositions may be administered on an administration protocol to improve glucose tolerance (e.g., fasting glucose levels may be reduced and/or glucose metabolism may be improved), in some implementations. The described compositions may be administered on an administration protocol to increase ketone levels (e.g., blood and/or urine ketone concentrations). For example, the described compositions may be administered once a day, via a time released or extended release preparation, and/or multiple times a day. The described composition may replace other pharmaceuticals taken for improving glucose tolerance, such as metformin, and/or be utilized in combination with one or more other pharmaceuticals, as appropriate.

In some implementations, an administration schedule may include administration of different berberine metabolite compositions at different periods. For example, berberine metabolite compositions may include at least a first composition and a second composition. The first composition may include dihydroberberine. The second composition may include dihydroberberine and a first additional compound that is capable of independently increasing blood ketone levels. The first composition may be administered to an individual for a first period of time and the second composition may be administered to the same individual for a second period of time. In some implementations, a third composition comprising dihydroberberine and a second additional compound that is different from the first additional compound may be administered. The first and other compositions (e.g., second and/or third composition) may be administered alternatively, sequentially, and/or in conjunction with each other (e.g., with a second and/or third composition). The compound formulations (e.g., dihydroberberine and/or which additional compounds are included) may be selected based on user preference (e.g., taste, diseases, sensitivities), desired results (e.g., fast induction of ketosis and/or maintenance), etc.

In various implementations, although a berberine metabolite such as dihydroberberine and/or tetrahydroberberine may be described, other forms of dihydroberberine and/or tetrahydroberberine may be administered such as salts, complexes, and/or derivatives thereof

Although various described systems and processes have been described as a being administered in humans, the described systems and processes may be administered to other mammals, such as rats, dogs, etc.

It is to be understood the implementations are not limited to particular systems or processes described which may, of course, vary. It is also to be understood that the terminology

used herein is for the purpose of describing particular implementations only, and is not intended to be limiting. As used in this specification, the singular forms "a", "an" and "the" include plural referents unless the content clearly indicates otherwise. Thus, for example, reference to "a beta-hydroxybutyrate" includes a combination of two or more beta-hydroxybutyrates and reference to "an additive" includes different types and/or combinations of additives.

Although the present disclosure has been described in detail, it should be understood that various changes, substitutions and alterations may be made herein without departing from the spirit and scope of the disclosure as defined by the appended claims. Moreover, the scope of the present application is not intended to be limited to the particular embodiments of the process, machine, manufacture, composition of matter, means, methods and steps described in the specification. As one of ordinary skill in the art will readily appreciate from the disclosure, processes, machines, manufacture, compositions of matter, means, methods, or steps, presently existing or later to be developed that perform substantially the same function or achieve substantially the same result as the corresponding embodiments described herein may be utilized according to the present disclosure. Accordingly, the appended claims are intended to include within their scope such processes, machines, manufacture, compositions of matter, means, methods, or steps.

The invention claimed is:

1. A method of managing glucose tolerance in an individual, the method comprising:

administering, to an individual, a pharmaceutically effective amount of dihydroberberine, wherein the pharmaceutically effective amount of dihydroberberine comprises approximately 25 mg to approximately 800 mg of dihydroberberine.

2. The method of claim **1** wherein the administration of dihydroberberine reduces fasting glucose levels.

3. The method of claim **1** wherein the dihydroberberine is administered as a complexed composition, and wherein the complexed composition further comprises at least one of complexed phytosomes or liposomes.

4. The method of claim **1** wherein the dihydroberberine is a microemulsion including dihydroberberine.

5. The method of claim **1** wherein the dihydroberberine is orally administered as a capsule or tablet.

6. The method of claim **1** wherein the dihydroberberine is orally administered as at least one of a food product or beverage product.

7. The method of claim **1** wherein the dihydroberberine is administered at least once daily.

8. The method of claim **1** further comprising administrating a Cytochrome P450 inhibitor, wherein administration of the Cyctochrome P450 inhibitor allows decreasing of the amount of dihydroberberine administered to be sufficient to achieve the desired results.

9. A method of increasing blood ketone levels in an individual, the method comprising:

administering, to an individual, a pharmaceutically effective amount of dihydroberberine, wherein the pharmaceutically effective amount of dihydroberberine comprises approximately 25 mg to approximately 800 mg of dihydroberberine.

10. The method of claim **9** wherein the dihydroberberine is administered approximately concurrently with meals.

11. The method of claim **9** further comprising administrating, to the individual, a pharmaceutically effective amount of one or more additional compounds capable of independently increasing blood ketone levels.

12. The method of claim **11** wherein the dihydroberberine and at least one of the additional compounds are administered approximately concurrently.

13. The method of claim **11** wherein the dihydroberberine and one or more of the additional compounds are administered at least one time daily.

14. The method of claim **9** wherein the pharmaceutically effective amount of dihydroberberine is administered with one or more additional compounds, and wherein one or more of the additional compounds comprises at least one of a beta-hydroxybutyrate, butyrate, a fatty acid, or ester of fatty acid, and wherein the amount of dihydroberberine administered to be pharmaceutically effective is less than the amount of dihydroberberine administered to be pharmaceutically effective when the dihydroberberine is administered without at least one of the additional compounds.

15. The method of claim **14** wherein at least one of the additional compounds comprises a R-beta-hydroxybutyrate compound.

16. The method of claim **14** wherein one or more of the additional compounds comprises at least one of a beta-hydroxybutyrate salt or beta-hydroxybutyrate polymer.

17. The method of claim **14** wherein the dihydroberberine and at least one of the additional compounds are administered approximately concurrently.

18. The method of claim **14** wherein the composition comprises at least two of the additional compounds, and wherein two or more of the additional compounds comprises a beta-hydroxybutyrate and at least one of a fatty acid or ester of a fatty acid.

19. The method of claim **1** wherein the pharmaceutically effective amount of dihydroberberine is administered with one or more additional compounds, and wherein one or more of the additional compounds comprises at least one of a beta-hydroxybutyrate, butyrate, a fatty acid, or ester of fatty acid.

20. The method of claim **9** wherein the pharmaceutically effective amount of dihydroberberine is administered with a beta-hydroxybutyrate and a medium chain fatty acid.

* * * * *

EXHIBIT 11

Shawna M. Bates

THE LAW OFFICE OF SHAWNA M. BATES, PLLC

The Law Office of Shawn M. Bates
7017 Emerald Creek Drive
McKinney, Texas 75071

September 12, 2024

Bonerge Lifesciences Co. Ltd.
Bld # 7B, Depu Parkview, E&D Zone
Changsha, Hunan China 414000

Dear Sir/Madam,

I am writing on behalf of my client, NNB Nutrition, which holds a granted patent related to dihydroberberine (DHB). It has come to our attention that your official website contains information that appears to be related to NNB Nutrition's patented technology.

The patent involved is:

1. **US Patent No. US10278961B2**: Administration of Berberine Metabolites.

Corresponding Information on Your Website

Based on our review, it seems that the following content on your website may correspond to the claims of NNB Nutrition's patent:

US Patent No. US10278961B2:

1. **Claim 1**: A method of managing glucose tolerance in an individual, comprising administering a pharmaceutically effective amount of dihydroberberine.
2. **Claim 2**: The method reduces fasting glucose levels.

Use of NNB Nutrition's Research

Additionally, it has been noted that your website uses data from NNB Nutrition's published clinical trials without proper citation or acknowledgment of the source. This data appears to be directly referenced from NNB Nutrition's publications and is used to support your product claims.

Requests

1. **Immediate Cessation**: We request that Bonerge Lifesciences immediately cease using NNB Nutrition's patented technology and data without proper authorization.

The Law Office of Shawna M. Bates | Phone: 469-305-0663 | email: info@SMBlegalcounsel.com | www.SMBlegalcounsel.com

2. **Proper Attribution**: Any future use of NNB Nutrition's data must include appropriate citation and acknowledgment of the source.
3. **Removal of Current Content**: We request the removal or correction of any current content on your website or promotional materials that improperly uses NNB Nutrition's data.

Conclusion

NNB Nutrition is committed to protecting its intellectual property rights and will take all necessary legal actions to enforce them. We trust that Bonerge Lifesciences will comply with the above requests promptly to avoid further legal action.

Please confirm in writing within 14 days of receipt of this letter that you have complied with these requests. Failure to do so will result in NNB Nutrition taking appropriate legal action to protect its rights.

Sincerely,

Shawna M. Bates

Shawna M. Bates
Attorney at Law
The Law Office of Shawna M. Bates
1-(469) 305-0663
sbates@smblegalcounsel.com

EXHIBIT 12

Shawna M. Bates

THE LAW OFFICE OF SHAWNA M. BATES, PLLC

The Law Office of Shawn M. Bates
7017 Emerald Creek Drive
McKinney, Texas 75071

October 29, 2024

Bonerge Lifesciences Co. Ltd.
Bld # 7B, Depu Parkview, E&D Zone
Changsha, Hunan, China 414000

Dear Sir/Madam,

I am writing again on behalf of my client, NNB Nutrition, which holds a granted patent related to dihydroberberine (DHB). It has come to our attention that despite our prior notice sent on September 12, 2024, Bonerge Lifesciences has not ceased its infringing activities.

Further, we have observed your continued infringement at the SupplySide West event held in Las Vegas, where Bonerge Lifesciences displayed materials and products that directly infringe upon NNB Nutrition's patent. This is a clear disregard of our previous request and a violation of NNB Nutrition's intellectual property rights.

As previously mentioned, the patent involved is:

- **US Patent No. US10278961B2: Administration of Berberine Metabolites**
- **US Patent No. US1903932: Use of Dihydroberberine or Its Derivatives to Improve Muscle Function**

We reiterate our demands:

1. **Immediate Cessation**: Bonerge Lifesciences must immediately cease all use, display, and promotion of products involving NNB Nutrition's patented technology without proper authorization.
2. **Proper Attribution**: Any future use of NNB Nutrition's data or related claims must include proper citation and acknowledgment.

The Law Office of Shawna M. Bates | Phone: 469-305-0663 | email: info@SMBlegalcounsel.com | www.SMBlegalcounsel.com

3. **Removal of Infringing Content**: All materials, including website content, promotional items, and displays at trade shows like SupplySide West, that use NNB Nutrition's patented claims or data must be corrected or removed immediately.

Failure to comply will result in NNB Nutrition taking legal action to enforce its rights. We expect a written response within 7 days of receipt of this letter confirming compliance with our demands. Continued non-compliance will escalate the matter further.

Sincerely,

Shawna M. Bates
Attorney at Law
The Law Office of Shawna M. Bates
1-(469) 305-0663
sbates@smblegalcounsel.com

EXHIBIT 13

Shawna M. Bates

THE LAW OFFICE OF SHAWNA M. BATES, PLLC

November 4, 2024

The Law Office of Shawna M. Bates
7017 Emerald Creek Drive
McKinney, Texas 75071

Via Certified Mail & Email
Randy Carr, CPSM
Global Supply Chain Manager
Nature's Fusions
57 N 1380 W
Orem, UT 84057
randy@naturesfusions.com

RE: Cease and Desist – Infringement of Patent Rights

Dear Mr. Carr,

I am writing on behalf of my client Nanjing Nutrabuilding Bio-Tech Co., Ltd. (NNB Nutrition), which holds granted patents related to dihydroberberine. It has come to our attention that Nature's Fusions is manufacturing, marketing, and selling a product under the name "Dihydroberberine +" on the Amazon platform, promoting it with claims relating to cardiovascular and metabolic health support. This product appears to infringe upon NNB's proprietary technology and patents for dihydroberberine-based compositions.

Patent Information:

NNB Nutrition holds exclusive rights to **U.S. Patent No. 10,278,961 B2** titled "**Administration of Berberine Metabolites**," which protects certain dihydroberberine formulations and their applications. Your unauthorized use of our patented technology without express permission from NNB constitutes patent infringement under U.S. patent laws.

DEMAND

1. **Immediate Cessation**: Cease and desist from manufacturing, distributing, marketing, and/or selling any product containing or related to our patented dihydroberberine formulations or any other infringing product.
2. **Removal from Sales Platforms**: Remove all listings and advertisements for the "Dihydroberberine +" product from your Amazon Store and any other sales channels within ten (10) business days of the date of this letter.
3. **Confirmation of Compliance**: Provide written confirmation within ten (10) business days of your compliance with the above demands, detailing the actions taken to cease infringement.

4. **Manufacturer and Distribution Details**: Disclose the name of any customers or other entities involved in the production or distribution of the infringing product.

CONSEQUENCES OF NON-COMPLIANCE

If we do not receive a satisfactory response and full compliance with this demand by November 30, 2024, NNB Nutrition will have no choice but to pursue all available legal remedies, including seeking an injunction and monetary damages for willful infringement. Additionally, any delay in compliance may expose your company to enhanced damages and legal costs.

We are willing to explore licensing opportunities if Nature's Fusions wishes to continue selling a dihydroberberine product under proper authorization from NNB Nutrition. Should you be interested in discussing a Trademark License and Supply Agreement with our exclusive manufacturer, please indicate your interest in your response.

We trust that you will comply with our demands promptly to avoid escalation of this matter.

Sincerely,

Shawna M. Bates

Shawna M. Bates
Attorney for NNB Nutrition
SMB Legal Counsel
7017 Emerald Creek Drive
McKinney, TX 75070
sbates@smblegalcounsel.com
Tel: 469-305-0663

Cc: Nanjing Nutrabuilding Bio-Tech Co., Ltd.

EXHIBIT 14

From: matt@naturesfusions.com
Sent: 11/6/2024 11:53:57 AM
To: Shawna Bates; Angela Walker; 'AG Bonerge'; Cecilia.Y@bonerge.com
Subject: RE: Infringement of Patent Rights

Shawna,

Thank you for your communication regarding your client's patents. We take such matters very seriously, and I work closely with a U.S. Patent lawyer who specializes in dietary supplements and patent law. With several patents pending of our own, our legal counsel and I have extensive experience navigating patent coverage, protection, infringement, and non-infringement considerations. We also have licensing agreements with other suppliers, giving us a well-rounded perspective on IP compliance and respect.

Our review of your client's patents indicates they cover specific methods of use for dihydroberberine. These include:

- "A method of managing glucose tolerance in an individual"
- "A method of increasing blood ketone levels in an individual"
- "A method for enhancing muscle function in a mammal"

Additionally, we understand that your client's pending patents cover other targeted uses, such as anti-aging, controlling weight, treating diabetes, and anti-glycation.

As is widely recognized, patent protection extends only to the specific language and scope of claims as outlined in the claims section. Infringement is determined based on whether a product or method uses the same function, in the same way, to achieve the same result as the patented claims. Here, your client's patents cover particular methods of use only, not the ingredient itself for any and all potential applications.

Our proprietary product is formulated with clinical backing and patents pending to address distinct applications. Specifically, our product's functionality, intended results, and underlying methods do not overlap with those claimed by your client. Our product performs a different clinically studied function/method, to achieve different outcomes than those described in your client's patents. Additionally, our marketing is clear and specific, ensuring no overlap or confusion with the patented claims. Bonerge has conducted rigorous clinical trials to substantiate the unique applications of our ingredient, providing clear support for our product's distinct method and usage.

Cecilia from our manufacturer, who has also worked extensively with U.S. patent laws, is copied here and available for further questions.

If there are specific claims we may have overlooked or if there is any additional information related to your allegations, please let us know. We would also appreciate any evidence demonstrating the alleged patent infringement.
We value compliance highly, as reflected in our own patent applications and in our multiple signed licensing agreements for other ingredients.

Thank you for your attention to this matter. We look forward to resolving this amicably.

Matt Peterson - CMO
Nature's Fusions Nutri
matt@naturesfusions.com
www.naturesfusions.com

From: Shawna Bates <sbates@smblegalcounsel.com>
Sent: Wednesday, November 6, 2024 8:22 AM
To: matt@naturesfusions.com; Angela Walker <awalker@smblegalcounsel.com>; 'AG Bonerge' <allen.g@bonerge.com>
Subject: RE: Infringement of Patent Rights

Matt,

I would advise that you speak with your attorney—one that understands US Patent and Trademark law.

Respectfully,
Shawna M. Bates

Book an appointment or schedule a call.



O: 469-305-0663 | M: 903-360-7587 | www.smblegalcounsel.com

This message, including attachments, is confidential and may contain information protected by the attorney-client privilege or work product doctrine. If you are not the addressee, any disclosure, copying, distribution, or use of the contents of this message are prohibited. If you have received this email in error, please destroy it and notify me immediately. Any tax advice contained in this message is not intended or written to be used, and cannot be used, for the purpose of (1) avoiding penalties under the internal revenue code or (2) promoting, marketing, or recommending to others any tax-related matter(s) addressed here.

From: matt@naturesfusions.com <matt@naturesfusions.com>
Sent: Tuesday, November 5, 2024 6:08 PM
To: Angela Walker <awalker@smblegalcounsel.com>; Shawna Bates <sbates@smblegalcounsel.com>; 'AG Bonerge' <allen.g@bonerge.com>
Subject: RE: Infringement of Patent Rights

Angela,

You can speak with the manufacturer of the ingredient we use in our product. Allen from Bonerge.
No infringement of Patent rights has occurred. We are under an NDA and Trademark agreement with Bonerge for use of their proprietary ingredient and methods of use.

Matt

From: Angela Walker <awalker@smblegalcounsel.com>
Sent: Tuesday, November 5, 2024 2:50 PM
To: randy@naturesfusions.com
Cc: Shawna Bates <sbates@smblegalcounsel.com>
Subject: Infringement of Patent Rights

Hello,

Please find attached a letter regarding Nature's Fusions' infringement of patent rights.

Sincerely,


Angela Walker
Paralegal
Office: 866-394-1918

Shawna M. Bates
THE LAW OFFICE OF SHAWNA M. BATES

O: 469-305-0663 | M: 903-360-7587 | www.smblegalcounsel.com

This message, including attachments, is confidential and may contain information protected by the attorney-client privilege or work product doctrine. If you are not the addressee, any disclosure, copying, distribution, or use of the contents of this message are prohibited. If you have received this email in error, please destroy it and notify me immediately. Any tax advice contained in this message is not intended or written to be used, and cannot be used, for the purpose of (1) avoiding penalties under the internal revenue code or (2) promoting, marketing, or recommending to others any tax-related matter(s) addressed here.

EXHIBIT 15




Branded Ingredients

The trajectory from ambiguity to standardization is the journey of standards for new products, it is Bonerge's responsibility to set and promote recognized quality standards for product formulation.

BeFisetin® Fisetin

UltraUroTM Urolithin A

...® is the top quality of Fisetin in the ...ket. We make efforts to manufacture fisetin in an eco-friendly and cost-efficient way to…



LEARN MORE

metabolite produced by the metabolism of natural ellagitannins through intestinal microbiota, from multiple reports in top…

LEARN MORE

GlucoSober Dihydroberberine

GlucoSober Dihydroberberine is produced using a patented manufacturing process, with high purity, high content, high bulk density and excellent fluidity. Dihydroberberine is a hydrogenated bioactive form of berberine,…



LEARN MORE

MitoSober PQQ

PQQ(Pyrroloquinoline Quinone) is a beneficial supplement for supporting mitochondrial function and brain health as well as preventing oxidative stress. MitoSober PQQ is affirmed by FDA GRAS and produced in a GMP…



LEARN MORE

NADHelp+ NAD

NADHelp+ is the brand name of NAD+ promoter Ingredients launched by Bonerge. As the most promising substitute for NMN at present, NAD（Nicotinamide Adenine Dinucleotide） is expected to trigger a new…



NADHelp+ NMNH

NADHelp+ is the brand name of NAD promoter Ingredients launched by Bonerge. NMNH (Reduced Beta-nicotinamide mononucleotide) is the newest popular NAD precursor that results in increased NAD+ levels effectively.…



NADHelp+ NMN

NADHelp+ is the brand name of NAD promoter Ingredients launched by Bonerge. NMN (Beta-nicotinamide mononucleotide) is the closest structurally to NAD, NMN supplementation results in increased NAD+ levels effectively.



LEARN MORE

NADHelp+ NR

NADHelp+ is the brand name of NAD promoter Ingredients launched by Bonerge. NADHelp+ NR (Nicotinamide Riboside) is the NAD precursor that results in increased NAD+ levels, and NR can go directly to cells.



LEARN MORE

NADHelp+ Apigenin

NADHelp+® is the brand name of NAD promoter Ingredients launched by Bonerge following compendial guidelines. NADHelp+ Apigenin is the top quality of Apigenin 98%, Apigenin has been found to be a good inhibit…



LEARN MORE

CitruSays® Nobiletin

Citrus Aurantium Extract std. to Nobiletin 10%-98% and PMFs(Nobiletin+Tangeretin) 30%-90%; Multiple specifications and customization available; The best quality and the most cost-effective Nobiletin.



LEARN MORE

lopment

StanYouth®, Longevity Matrix under development

STANYOUTH

LEARN MORE

BONERGE

Bontanical Energy for Healthy Aging
Quality,Safety and Love of Life

Quick Links

About Us
BongeLov System
News & Articles
BeFisetin

Our Products

Branded Ingredients
Featured Ingredients
Classic Ingredients

Disclaimer: All health claims are based on scientific research and are not intended to diagnose, cure or prevent any disease.

Contact Info


2049 S. Hellman Ave, Unit A, Ontario CA 91761, USA

+1 (949) 712-7328

sales@bonerge.com

Join us

EXHIBIT 16



GlucoSober Dihydroberberine

GLUCOSOBER

GlucoSober is the brand name for high quality Dihydroberberine developed by Bonerge.

★ GlucoSober, with patented technology, has a content of more than 98% when analyzed by the Sigma reference standard.;


★ GlucoSober Dihydroberberine has a unique crystal form, with a bulk density of more than 0.6g/ml, and exhibits excellent flowability and stability.

large amounts of scientific research showing significant improvements of GLP-1 sensitivity, HbA1c reduction, nutrient partitioning, and far more;

★ Improves cardiovascular health, and cellular longevity by modulating various pathways and receptors.

The basic information

Brand Name	**GlucoSober**
Product Name	Dihydroberberine
Specification	**Powder: Assay 98%, bulk density 0.3g/ml** **Granular: Assay 98%, bulk density 0.6g/ml**
Sterilization	Dry heat. Non-irradiated.



The Quality Control

Quality standards, including physical, chemical, and microbiological tests and criteria are important parts of the safety and efficacy of ingredients. Bonerge is aiming to offer premium-quality Dihydroberberine ingredients with potent healthy values to the world.



1. BongeLov Management System

All of our products are developed and operated under our BongeLov Management System. We are proud to hold and maintain a full set of the world-class manufacturing certifications including cGMP, GMP+, FSSC22000, HACCP, ISO22000, Halal, Kosher etc, our process allows Bonerge to continue to meet the highest standards for purity, traceability and transparency that's backed by strict controls, monitoring and tracking to provide our customers with products they trust.

2. Analytical Procedure Life Cycle Management

With professional analytical scientists and advanced equipments, top quality and consistency among batches are the golden promises to our customers from Bonerge.

The identity test, purity test, impurity test and assay test that usually applied in the pharmaceutical industry and guided by USP requirements, is at the center of Bonerge's quality research.


3. Authoritative and credible Reference Standard(RS) for assay analysis

4. [illegible]quality botanical source for eco-friendly and cost-efficiently manufacturing

We are making efforts to manufacture eco-friendly and cost-efficiently to make our healthy ingredients more affordable to consumers. We work with the raw material growers closely to source high quality material that can be traced through every step. Our facility equipped with two continuous countercurrent extraction lines, and each line is available in capacities of up to hundreds tons/day raw material, enable us to produce at super largre scale and achive the best quality and cost.


The Benefits Research

★ Dihydroberberine is super Berberine, there are studies advice that the bioavailability of Dihydroberberine is 4.8 times better than Berberine.



★ And studies shows the effects of Dihydroberberine are superior to those of berberine in the following aspects:


DHB has a better effect on reducing visceral fat



In mice fed an HFD(high fat diet), treatment with DHB(100 mg/kg/day) markedly reduced adiposity (epididymal fat, muscle fat, liver fat) and improved glucose tolerance, compared with HFD controls. At the same dose, BBR had no effect on adiposity or glucose tolerance.

Diabetes, Vol57, May 2008, 1417.


DHB has a better effect on anti-atherosclerosis



The in vivo study evaluate anti−atherosclerotic effects of BBR and DHB. The result showed that DHB reduced aortic atherosclerotic lesion size, improved plaque stability when compared with control group. However, BBR at the same dosage did not show beneficial effect.

Journal of Translational Medicine 2014, 12:326.

DHB has a be on anti-colitis



The goblet cells produce and secrete mucus to maintain the colon mucosal barrier. In vitro studies showed that the loss of goblet cells caused by DSS were significantly reversed by DHB, and AZA (a commonly used drug for colitis) treatments. The effect of DHB (at a dose of 50 mg/kg) is better than that of BBR and comparable to that of a 13 mg/kg dose of AZA.

Phytomedicine 90 (2021) 153631.

BONERGE

Bontanical Energy for Healthy Aging Quality,Safety and Love of Life

Quick Links

About Us
BongeLov System
News & Articles
BeFisetin

Our Products

Branded Ingredients
Featured Ingredients
Classic Ingredients

Disclaimer: All health claims are based on scientific research and are not intended to diagnose, cure or prevent any disease.

Contact Info

2049 S. Hellman Ave, Unit A, Ontario CA 91761, USA

+1 (949) 712-7328

sales@bonerge.com

Join us

EXHIBIT 17

BONERGE

CONTACT



Dihydroberberine 97% HPLC

★ Berberine is one of the best known and most effective natural Glucose Disposal Agents.

★ With large amounts of scientific research showing significant improvements of Berberine to insulin sensitivity, fasting glucose levels, HbA1c reduction, nutrient partitioning, and far more.

★ Research suggests that dihydroberberine is up to 5 times better than standard berberine, bringing incredible effects at lower doses - and fewer side effects.

The Brief Info

Product Name	**Dihydroberberine (Powder & Granular)**
Specification	**Powder: Purity NLT 97% by HPLC** **Granular: Purity NLT 95% by HPLC**
Botanical source	*Berberis Aristata,* Family Berberidaceaetract
Sterilization	Dry heat. Non-irradiated.
GMO	Non-GMO.
BSE/TSE	Not of animal origin.BSE TSE free.
Allergen	Known allergen free.
Gluten	Gluten free.
Storage	Store in a cool dry place,away from direct sunlight

BONERGE

CONTACT



The Detail

Dihydroberberine Helps To Improve Glucose and Lipid Metabolic Health

Until now, there are large amounts of scientific research showing that in reduce blood sugar levels; promote lipid conversion; help for loss weight, **Dihydroberberine(DHB) has better effect than Berberine(BBR).**

1. Maintain Blood Sugar Standard

BBR has been showen to adjust Sugar metabolism in human body through reduced glucose absorption; inhibit gluconeogenesis; regulate insulin levels; active PKC and AMPK.

DHB shows better effect than BBR in adjust sugar metabolism, a study, which the subjects were mice shows BBR and DHB all can improve 44% insulin sensitivity. Compared with DHB and BBR for improving insulin sensitivity. The results shows that to cause the same reaction with DHB, you need five times more than BBR.

2. Lipid Metabolism

reduce the risk of heart disease, this is thought to be caused by BBR's inhibitor enzyme called PCSK9, which when inhibited causes more LDL (bad cholesterol) to be removed from the blood.

One study compared the pancreatic lipase inhibition of BBR and DHB, the results shows that because of the affinity of DHB is stronger than BBR, the BBR has a lower inhibitory action compared to DHB on pancreatic lipase.

3. Weight Loss and Prevent Obesity

BBR can regulate blood glucose and lipid balance in many ways, indicating that it can help regulate body weight. In one study, subjects were given BBR over time, after 12 weeks, their BMI levels dropped from 31.5 to 27.4. DHB has stronger ability in these aspect,so DHB may be considered a more effective weight-loss aid than BBR.

Reference

1. Wang Y, Campbell T, Perry B, Beaurepaire C, Qin L (2011) Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet- and streptozotocin-induced diabetic rats. Metabolism 60: 298-305.

2. Turner N, Li JY, Gosby A, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes. 2006 Mar;55(3):708-15. doi: 10.2337/diabetes.55.03.06.db05-0312.

3. Paavola, K.J. and R.A. Hall, (Polygala Tenuifolia)receptors: signaling, pharmacology, and mechanisms of activation. Molecular pharmacology, 2018. 82(5): p. 777-783.

BONERGE

CONTACT

BONERGE

Bontanical Energy for Healthy Aging
Quality,Safety and Love of Life

Quick Links

About Us
BongeLov System
News & Articles
BeFisetin

Our Products

Branded Ingredients
Featured Ingredients
Classic Ingredients

Disclaimer: All health claims are based on scientific research and are not intended to diagnose, cure or prevent any disease.

Contact Info

2049 S. Hellman Ave, Unit A, Ontario CA 91761, USA

+1 (949) 712-7328

sales@bonerge.com

Join us

EXHIBIT 18

Promotional Feature



BONERGE
Botanical Energy for Healthy Aging

Paid for and content provided by Bonerge Lifescience

Learn more

The following content is provided by an advertiser or created on behalf of an advertiser. It is not written by the NutraIngredients-USA editorial team, nor does it necessarily reflect the opinions of NutraIngredients-USA.
For more information, please contact us here

Dihydroberberine a bioavailable form of berberine for glucose control

08-Jan-2025 Last updated on 08-Jan-2025 at 16:26 GMT

With the evolution of the food industry and modern lifestyle changes, health issues such as obesity, diabetes, and cardiovascular disease have become significant threats to health and wellbeing.

These health issues might be caused by metabolic disorders or metabolic syndrome.[1] Therefore, keeping a healthy metabolic function, especially blood glucose level, is the key to health management.

These issues not only impact individual health and quality of life but also place a substantial burden on society and the healthcare system. In response, brands have introduced various products to address weight loss and blood glucose control needs. Berberine has gained popularity for its multiple health benefits, including blood glucose and lipid regulation capabilities.

Since 2022, berberine has gone viral on TikTok in the US, catalyzed by a user sharing her successful weight loss journey with the supplement. These short videos garnered widespread attention, and the internet quickly dubbed berberine 'Nature's Ozempic'.

Experiences related to weight loss using berberine amassed billions of views, leading to a dramatic surge in demand. Many berberine products sold out, even causing a shortage of raw materials.

Berberine: The natural glucagon-like peptide-1 (GLP-1) stimulator

Berberine, primarily derived from plants with a long history of use, was first recorded in ancient Chinese medical 'Shen-nong's Herbal Classics' over 3,000 years ago.

In recent years, modern science has gradually uncovered various pharmacological effects of berberine, leading to its widespread use in clinical practice. Research has found that berberine exerts its health benefits through several mechanisms:

Key benefits of berberine and related health benefits:

1. Promotes GLP-1 secretion

- Increases GLP-1 secretion by promoting the expression of glucagon mRNA and the proliferation of intestinal L-cells.[2]
- Activates the bitter taste receptor TAS2R38 in the intestine, stimulating GLP-1 secretion from L-cells.[2]

2. Regulates blood sugar metabolism and improves insulin resistance

- Stimulates insulin receptor expression, enhances insulin sensitivity and improves insulin resistance.[3]
- Upregulates glucose transporter type 4 (Glut4) expression, promoting glucose uptake by cells and reducing blood glucose levels.[4]
- Reduces oxygen consumption and ATP production in mitochondria, and inhibits the expression of gluconeogenesis transcription factors (G6Pase and PEPCK), thereby lowering fasting blood sugar levels.[5]

3. Increases brown fat content and improves fat metabolism

- Promotes the expression of browning genes in white adipose tissue, increasing brown fat quantity and enhancing brown tissue function, leading to increased energy expenditure and thermogenesis.[6]

levels and improving fat metabolism.[7–8]

4. Regulates cholesterol metabolism

- Downregulates the expression of acyl-CoA cholesterol acyltransferase-2, reducing cholesterol uptake and cell monolayer permeability.[9]
- Upregulates the gene expression of sterol 27-hydroxylase and cholesterol-7α-hydroxylase, inhibiting intestinal cholesterol absorption.[10]
- Lowers levels of plasma LDL cholesterol, free fatty acids (FFAs), and total cholesterol via the AMPK pathway while increasing HDL cholesterol levels.[11–12]

5. Reduces inflammation and oxidative stress damage

- Exerts anti-inflammatory effects by inhibiting cyclooxygenase-2 expression through the suppression of AP-1 binding.[13]
- Modulates oxidative stress markers and antioxidant enzyme levels through complex mechanisms like AMPK activation, NF-κB and AP-1 pathway inhibition, and Nrf2 pathway regulation, reducing pro-inflammatory cytokine levels.[13]

The limitations of berberine in practical applications

Despite the huge enthusiasm for berberine, scientific studies have found limitations in its application, such as low bioavailability, poor intestinal absorption, and potential irritations on the GI tract.[14]

Sub-chronic toxicity of berberine indicates the potential damage of lung and liver in animal at very high dosage.[15] This has motivated Bonerge to step forward to test the safety of Berberine and Dihydroberberine.




Figure 1: Reasons causing limited bioavailability of Berberine.[16]

Dihydroberberine: A more bioavailable form of berberine

Dihydroberberine is a research-proven bioactive form of berberine derivative. When berberine is orally ingested, it is reduced to Dihydroberberine in the intestine, absorbed through the intestinal wall, and then converted back to berberine in the blood to exert its effects. Thus, Dihydroberberine can be absorbed more rapidly by the intestinal wall, resulting in higher bioavailability compared to berberine.[17]




Figure 2: Berberine absorption mechanism in intestine.[17]

Although Dihydroberberine is a relatively new product for the weight-loss market, its efficacy has been proven by both in vivo and in vitro studies. Dihydroberberine has a better absorption rate and greater potency than berberine.[17]

Better absorption efficiency

- In vitro studies using the Caco-2 cell model of human colon cancer cells show that Dihydroberberine's absorption rate is 11.9 times that of berberine, with an efflux ratio 1/20 of berberine.[17]
- In a study conducted on mice, the absorption blood concentration curve area AUC(0-t) of Berberine is 54.57, while the AUC(0-t) of Dihydroberberine is 261.8, indicating that the bioavailability of Dihydroberberine is 4.8 times that of berberine.[17]

Better health benefits

cardiovascular health.[15–16] The stable, high-quality GlucoSober™ Dihydroberberine is a promising product that delivers the fuller range of health benefits associated with Dihydroberberine.

Enhanced insulin sensitivity Dihydroberberine improves whole-body insulin sensitivity in HFD rats by increasing the uptake of glucose into peripheral tissues. The glucose infusion rate was 44% higher in the Dihydroberberine-treated group compared with the HFD control group.[18]

Better body fat loss Dihydroberberine supplementation can markedly reduce adiposity while at the same dose, berberine had no effect.[18]

Better atherosclerosis effect Research shows that Dihydroberberine is better at inhibiting inflammation and reducing atherosclerotic plaque size and vulnerability. This indicates that Dihydroberberine reduces plaque area in mice arteries by 44.4%, while berberine reduces it by 15.5%.[19]

Better anti-colitis effect Dihydroberberine treatment effectively alleviates ulcerative colitis by relieving clinical manifestation better than berberine via a similar beneficial effect to azathioprine. 25 mg/kg Dihydroberberine was as effective as a 50 mg/kg dose of Berberine.[20]

Improved quality Dihydroberberine cuts handling troubles

Bonerge Lifescience has initiated the patent application process for GlucoSober® – a high-quality Dihydroberberine ingredient tailored to fulfill the escalating market demand for berberine.

Relatively speaking, Dihydroberberine is a newcomer in the market, and the quality varies significantly among different suppliers. Owing to its high bioactivity

Furthermore, similar to many powder ingredients, regular Dihydroberberine tends to agglomerate when exposed to moisture and generates static electricity during encapsulation. This leads to excessive production losses and poses challenges in cleaning equipment.

To overcome the issues of Dihydroberberine's light sensitivity and clumping, Bonerge has developed GlucoSober, accomplished through a patent-pending manufacturing process.

GlucoSober is more stable, possesses better fluidity, has fewer impurities, and both its purity and content exceed 98%. Additionally, there is a distinctive high-density granulation specification of GlucoSober (bulk density greater than 0.6 g/ml), which can enhance the processing efficiency for the production of tablets and capsules.




Figure 3: GlucoSober vs. Dihydroberberine from other supplier

value of berberine and Dihydroberberine in blood glucose metabolism and weight management.

Bonerge will persist in investing in product research and evidence-based active ingredients, collaborating with global partners to select GlucoSober. Bonerge are motivated by the delight of witnessing consumers deriving health benefits from its ingredients, which inspires innovation.

References

1. Mayo Clinic, Mayo Foundation for Medical Education and Research. Metabolic Syndrome.
2. Yu, Y.; et al. Berberine induces GLP-1 secretion through activation of bitter taste receptor pathways. Biochem Pharmacol, 2015, 97(2): 173-7.
3. Kong, W. J.; et al. Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Metabolism, 2009, 58(1): 109-19.
4. Mi, J.; et al. Effect of berberine on the HPA-axis pathway and skeletal muscle GLUT4 in type 2 diabetes mellitus rats. Diabetes Metab Syndr Obes, 2019, 12: 1717-25.
5. Xia, X.; et al. Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PLoS One, 2011, 6(2): e16556.
6. Zhang, Z.; et al. Berberine activates thermogenesis in white and brown adipose tissue. Nat Commun, 2014, 5: 5493.
7. Ren, G.; et al. Berberine Improves Glucose and Lipid Metabolism in HepG2 Cells Through AMPKalpha1 Activation. Front Pharmacol, 2020, 11: 647.
8. Zhu, X.; et al. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway. Free Radic Biol Med, 2019, 141: 192-204.
9. Wang, Y.; et al. Berberine decreases cholesterol levels in rats through multiple mechanisms, including inhibition of cholesterol absorption. Metabolism, 2014, 63(9): 1167-77.

11. Kim, W S.; et al. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab, 2009, 296(4): E812-9.

12. Jiang, D.; et al. Berberine increases adipose triglyceride lipase in 3T3-L1 adipocytes through the AMPK pathway. Lipids in Health and Disease, 2016, 15(1).

13. Zou, K.; et al. Advances in the study of berberine and its derivatives: a focus on anti-inflammatory and anti-tumor effects in the digestive system. Acta Pharmacol Sin, 2017, 38(2): 157-67.

14. Berberine. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. U.S. National Library of Medicine, 6 Oct. 2020.

15. Ning, N.; et al. Pharmacological and safety evaluation of fibrous root of Rhizoma Coptidis. *Environ Toxicol Pharmacol*. 2015;39(1):53-69.

16. Xu, H-Y.; et al. Nanoemulsion improves hypoglycemic efficacy of berberine by overcoming its gastrointestinal challenge. Colloids and Surfaces B: Biointerfaces, 2019, 181: 927-34.

17. Feng, R.; et al. Transforming berberine into its intestine-absorbable form by the gut microbiota. Scientific Reports, 2015, 5(1).

18. Turner, N.; et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes, 2008, 57(5): 1414-8.

19. Chen, J.; et al. Berberine derivatives reduce atherosclerotic plaque size and vulnerability in apoE−/− mice. 2014, 12: 1-13.

20. Li C.; et al. Dihydroberberine, an isoquinoline alkaloid, exhibits protective effect against dextran sulfate sodium-induced ulcerative colitis in mice. Phytomedicine, 2021, 90.

Additional references

Li, Z.; et al. Antioxidant and Anti-Inflammatory Activities of Berberine in the Treatment of Diabetes Mellitus. Evidence-Based Complementary and Alternative

NutraIngredients USA

More from Bonerge Lifescience



Urolithin A: Why the gold standard is key for a healthy market

Paid for and content provided by Bonerge Lifescience



High active fisetin is the next anti-aging superstar

Paid for and content provided by Bonerge Lifescience

NutraIngredients-USA

Advertise with us

Apply to reuse our content

Press Releases - Guidelines

About us

Contact us

Why NI?

Resources

Report a technical problem

Whitelist our newsletters

Help Centre

RSS Feed

Podcast

NutraIngredients USA

William Reed.

© William Reed Ltd 2025. All rights reserved.

Registered Office: Broadfield Park, Crawley RH11 9RT. Registered in England No. 2883992. VAT No. 644 3073 52.

Website Terms | Privacy Notice | Cookie Statement | Cookie Preferences

aop 2021 B2B DIGITAL PUBLISHER OF THE YEAR

EXHIBIT 19

Generated on: This page was generated by TSDR on 2024-11-19 15:09:01 EST

Mark: GLUCOSOBER

GlucoSober

US Serial Number: 98638859

Application Filing Date: Jul. 09, 2024

Filed as TEAS Plus: Yes

Currently TEAS Plus: Yes

Register: Principal

Mark Type: Trademark

TM5 Common Status Descriptor:



LIVE/APPLICATION/Under Examination

The trademark application has been accepted by the Office (has met the minimum filing requirements) and that this application has been assigned to an examiner.

Status: Approved by the examining attorney for publication but has not yet published for opposition. Although rare, withdrawal of approval prior to publication may occur after final review. The opposition period begins on the date of publication.

Status Date: Nov. 15, 2024

Mark Information

Mark Literal Elements: GLUCOSOBER

Standard Character Claim: Yes. The mark consists of standard characters without claim to any particular font style, size, or color.

Mark Drawing Type: 4 - STANDARD CHARACTER MARK

Goods and Services

Note:
The following symbols indicate that the registrant/owner has amended the goods/services:

- Brackets [..] indicate deleted goods/services;
- Double parenthesis ((..)) identify any goods/services not claimed in a Section 15 affidavit of incontestability; and
- Asterisks *..* identify additional (new) wording in the goods/services.

For: Dietary beverage supplements for human consumption in liquid and dry mix form for therapeutic purposes; Dietary supplement drink mixes; Dietary supplemental drinks; Dietary supplements; Dietary supplements for animals; Dietary supplements for humans; Dietary supplements for lowering glucose levels; Dietary supplements in the form of capsules, tablets, caplets, powder, liquids, syrups, gummies, gels and soft chews; Dietary supplements in the nature of weight loss powders; Dietary and nutritional supplements; Dietary and nutritional supplements used for weight loss; Dietary food supplements; Food supplements; Herbal supplements; Meal replacement bars for weight loss purposes; Nutritional food additives for medical purposes in the nature of natural food extracts derived from plants, fruits and vegetables; Nutritional supplements; Nutritional supplements for lowering glucose levels; Nutritional supplements in the form of capsules, tablets, caplets, powder, liquids, syrups, gummies, gels and soft chews; Plant extracts, other than essential oils, for medical, veterinary and pharmaceutical purposes; Plant extracts, other than essential oils, for pharmaceutical purposes; Plant and herb extracts, other than essential oils, for medicinal purposes; Powdered nutritional supplement concentrate; Powdered nutritional supplement drink mix; Glucose dietary supplements; Natural dietary supplements; Nutraceuticals for use as a dietary supplement; Nutritional and dietary supplements formed and packaged as bars; Nutritional supplement meal replacement bars for boosting energy; Vitamins and dietary food supplements for animals

International Class(es): 005 - Primary Class

U.S Class(es): 005, 006, 018, 044, 046, 051, 052

Class Status: ACTIVE

Basis: 1(b)

Basis Information (Case Level)

Filed Use: No

Currently Use: No

Filed ITU: Yes

Currently ITU: Yes

Filed 44D: No

Currently 44D: No

Filed 44E:	No	**Currently 44E:**	No
Filed 66A:	No	**Currently 66A:**	No
Filed No Basis:	No	**Currently No Basis:**	No

Current Owner(s) Information

Owner Name: Bonerge Lifescience (Hunan) Co., Ltd.

Owner Address: Bldg#7B, Depu Parkview, E&D Zone
Changsha, Hunan CHINA 414000

Legal Entity Type:	limited company (ltd.)	**State or Country Where Organized:**	CHINA

Attorney/Correspondence Information

Attorney of Record

Attorney Name: L. S. VanLandingham III

Attorney Primary Email Address:	Lsvanlan@hotmail.com	**Attorney Email Authorized:**	Yes

Correspondent

Correspondent Name/Address: L. S. VanLandingham III
91 Lakemaster Lane
Lake Havasu City, ARIZONA United States 86403

Phone: 928-453-0293

Correspondent e-mail:	Lsvanlan@hotmail.com	**Correspondent e-mail Authorized:**	Yes

Domestic Representative

** Domestic Representative Name:**	L. S. VanLandingham III	**Phone:**	928-453-0293
** Domestic Representative e-mail:**	Lsvanlan@hotmail.com	** Domestic Representative e-mail Authorized:**	Yes

Prosecution History

Date	Description	Proceeding Number
Nov. 15, 2024	APPROVED FOR PUB - PRINCIPAL REGISTER	
Nov. 15, 2024	EXAMINER'S AMENDMENT ENTERED	
Nov. 15, 2024	NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED	
Nov. 15, 2024	EXAMINERS AMENDMENT E-MAILED	
Nov. 15, 2024	EXAMINERS AMENDMENT -WRITTEN	
Nov. 14, 2024	ASSIGNED TO EXAMINER	96116
Jul. 09, 2024	NEW APPLICATION OFFICE SUPPLIED DATA ENTERED	
Jul. 09, 2024	NEW APPLICATION ENTERED	

TM Staff and Location Information

TM Staff Information

TM Attorney:	CHOI, REBECCA	**Law Office Assigned:**	LAW OFFICE 118

File Location

Current Location:	TMO LAW OFFICE 118	**Date in Location:**	Nov. 15, 2024

PTO- 1478
Approved for use through 10/31/2024. OMB 0651-0009
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Trademark/Service Mark Application, Principal Register

TEAS Plus Application

Serial Number: 98638859
Filing Date: 07/09/2024

NOTE: Data fields with the * are mandatory under TEAS Plus. The wording "(if applicable)" appears where the field is only mandatory under the facts of the particular application.

The table below presents the data as entered.

Input Field	Entered
TEAS Plus	**YES**
MARK INFORMATION	
***MARK**	GlucoSober
***STANDARD CHARACTERS**	YES
USPTO-GENERATED IMAGE	YES
LITERAL ELEMENT	GlucoSober
***MARK STATEMENT**	The mark consists of standard characters, without claim to any particular font style, size, or color.
REGISTER	Principal
APPLICANT INFORMATION	
***OWNER OF MARK**	Bonerge Lifescience (Hunan) Co., Ltd.
***MAILING ADDRESS**	Bldg#7B, Depu Parkview, E&D Zone
***CITY**	Changsha, Hunan
***COUNTRY/REGION/JURISDICTION/U.S. TERRITORY**	China
***ZIP/POSTAL CODE (Required for U.S. and certain international addresses)**	414000
***EMAIL ADDRESS**	XXXX
WEBSITE ADDRESS	www.bonerge.com
LEGAL ENTITY INFORMATION	
***TYPE**	limited company (ltd.)
***STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY WHERE LEGALLY ORGANIZED**	China
GOODS AND/OR SERVICES AND BASIS INFORMATION	
***INTERNATIONAL CLASS**	005
	Dietary beverage supplements for human consumption in liquid and dry mix form for therapeutic purposes; Dietary supplement drink mixes; Dietary supplemental drinks; Dietary supplements; Dietary supplements for animals; Dietary

*IDENTIFICATION	supplements for humans; Dietary supplements for **lowering glucose levels**; Dietary supplements in the form of **capsules, tablets, caplets, powder, liquids, syrups, gummies, gels and soft chews**; Dietary supplements in the nature of weight loss powders; Dietary and nutritional supplements; Dietary and nutritional supplements used for weight loss; Dietary food supplements; Food supplements; Herbal supplements; Meal replacement bars for weight loss purposes; Nutritional food additives for medical purposes in the nature of natural food extracts derived from **plants, fruits and/or vegetables**; Nutriti onal supplements; Nutritional supplements for **lowering glucose levels**; Nutritional supplements in the form of **capsule s, tablets, caplets, powder, liquids, syrups, gummies, gels and soft chews**; Plant extracts, other than essential oils, for medical, veterinary and pharmaceutical purposes; Plant extracts, other than essential oils, for pharmaceutical purposes; Plant and herb extracts, other than essential oils, for medicinal purposes; Powdered nutritional supplement concentrate; Powdered nutritional supplement drink mix; Glucose dietary supplements; Natural dietary supplements; Nutraceuticals for use as a dietary supplement; Nutritional and dietary supplements formed and packaged as bars; Nutritional supplement meal replacement bars for boosting energy; Vitamins and dietary food supplements for animals
*FILING BASIS	SECTION 1(b)
ADDITIONAL STATEMENTS SECTION	
*TRANSLATION (if applicable)	
*TRANSLITERATION (if applicable)	
*CLAIMED PRIOR REGISTRATION (if applicable)	
*CONSENT (NAME/LIKENESS) (if applicable)	
*CONCURRENT USE CLAIM (if applicable)	
SIGNIFICANCE OF MARK	GlucoSober appearing in the mark has no significance nor is it a term of art in the relevant trade or industry or as used in connection with the goods/services listed in the application, or any geographical significance.
SIGNIFICANCE OF MARK	The word(s) GlucoSober has no meaning in a foreign language.
ATTORNEY INFORMATION	
NAME	L. S. VanLandingham III
ATTORNEY BAR MEMBERSHIP NUMBER	XXX
YEAR OF ADMISSION	XXXX
U.S. STATE/ COMMONWEALTH/ TERRITORY	XX
STREET	91 Lakemaster Lane
CITY	Lake Havasu City
STATE	Arizona
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY	United States

ZIP/POSTAL CODE	86403
PHONE	928-453-0293
EMAIL ADDRESS	Lsvanlan@hotmail.com
DOMESTIC REPRESENTATIVE INFORMATION	
NAME	L. S. VanLandingham III
STREET	91 Lakemaster Lane
CITY	Lake Havasu City
STATE	Arizona
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY	United States
ZIP CODE	86403
PHONE	928-453-0293
EMAIL ADDRESS	Lsvanlan@hotmail.com
CORRESPONDENCE INFORMATION	
NAME	L. S. VanLandingham III
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE	Lsvanlan@hotmail.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES)	NOT PROVIDED
FEE INFORMATION	
APPLICATION FILING OPTION	TEAS Plus
NUMBER OF CLASSES	1
APPLICATION FOR REGISTRATION PER CLASS	250
***TOTAL FEES DUE**	250
***TOTAL FEES PAID**	250
SIGNATURE INFORMATION	
* **SIGNATURE**	/lsvanlandingham/
* **SIGNATORY'S NAME**	Leander S. VanLandingham III
* **SIGNATORY'S POSITION**	Attorney of record, Arizona Bar member
SIGNATORY'S PHONE NUMBER	928-453-0293
* **DATE SIGNED**	07/09/2024
SIGNATURE METHOD	Signed directly within the form

PTO- 1478
Approved for use through 10/31/2024. OMB 0651-0009
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Trademark/Service Mark Application, Principal Register

TEAS Plus Application

Serial Number: 98638859
Filing Date: 07/09/2024

To the Commissioner for Trademarks:

MARK: GlucoSober (Standard Characters, see mark)
The literal element of the mark consists of GlucoSober. The mark consists of standard characters, without claim to any particular font style, size, or color.
The applicant, Bonerge Lifescience (Hunan) Co., Ltd., a limited company (ltd.) legally organized under the laws of China, having an address of
Bldg#7B, Depu Parkview, E&D Zone
Changsha, Hunan 414000
China
XXXX

requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C. Section 1051 et seq.), as amended, for the following:

For specific filing basis information for each item, you must view the display within the Input Table.
International Class 005: Dietary beverage supplements for human consumption in liquid and dry mix form for therapeutic purposes; Dietary supplement drink mixes; Dietary supplemental drinks; Dietary supplements; Dietary supplements for animals; Dietary supplements for humans; Dietary supplements for lowering glucose levels; Dietary supplements in the form of capsules, tablets, caplets, powder, liquids, syrups, gummies, gels and soft chews; Dietary supplements in the nature of weight loss powders; Dietary and nutritional supplements; Dietary and nutritional supplements used for weight loss; Dietary food supplements; Food supplements; Herbal supplements; Meal replacement bars for weight loss purposes; Nutritional food additives for medical purposes in the nature of natural food extracts derived from plants, fruits and/or vegetables; Nutritional supplements; Nutritional supplements for lowering glucose levels; Nutritional supplements in the form of capsules, tablets, caplets, powder, liquids, syrups, gummies, gels and soft chews; Plant extracts, other than essential oils, for medical, veterinary and pharmaceutical purposes; Plant extracts, other than essential oils, for pharmaceutical purposes; Plant and herb extracts, other than essential oils, for medicinal purposes; Powdered nutritional supplement concentrate; Powdered nutritional supplement drink mix; Glucose dietary supplements; Natural dietary supplements; Nutraceuticals for use as a dietary supplement; Nutritional and dietary supplements formed and packaged as bars; Nutritional supplement meal replacement bars for boosting energy; Vitamins and dietary food supplements for animals
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services. (15 U.S.C. Section 1051(b)).

Significance of wording, letter(s), or numeral(s)
GlucoSober appearing in the mark has no significance nor is it a term of art in the relevant trade or industry or as used in connection with the goods/services listed in the application, or any geographical significance.

Significance of wording, letter(s), or numeral(s)
The word(s) GlucoSober has no meaning in a foreign language.

For informational purposes only, applicant's website address is: www.bonerge.com
The owner's/holder's proposed attorney information: L. S. VanLandingham III. L. S. VanLandingham III, is a member of the XX bar, admitted to the bar in XXXX, bar membership no. XXX, is located at
91 Lakemaster Lane
Lake Havasu City, Arizona 86403
United States
928-453-0293(phone)
Lsvanlan@hotmail.com

L. S. VanLandingham III submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.

The applicant hereby appoints L. S. VanLandingham III
91 Lakemaster Lane
Lake Havasu City Arizona 86403
United States
928-453-0293(phone)
Lsvanlan@hotmail.com
as applicant's representative upon whom notice or process in the proceedings affecting the mark may be served.

The applicant's current Correspondence Information:
L. S. VanLandingham III
PRIMARY EMAIL FOR CORRESPONDENCE: Lsvanlan@hotmail.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED

Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).
A fee payment in the amount of $250 has been submitted with the application, representing payment for 1 class(es).

Declaration

☑ **Basis:**
If the applicant is filing the application based on use in commerce under 15 U.S.C. § 1051(a):

- The signatory believes that the applicant is the owner of the trademark/service mark sought to be registered;
- The mark is in use in commerce and was in use in commerce as of the filing date of the application on or in connection with the goods/services in the application;
- The specimen(s) shows the mark as used on or in connection with the goods/services in the application and was used on or in connection with the goods/services in the application as of the application filing date; and
- To the best of the signatory's knowledge and belief, the facts recited in the application are accurate.

And/Or
If the applicant is filing the application based on an intent to use the mark in commerce under 15 U.S.C. § 1051(b), § 1126(d), and/or § 1126(e):

- The signatory believes that the applicant is entitled to use the mark in commerce;
- The applicant has a bona fide intention to use the mark in commerce and had a bona fide intention to use the mark in commerce as of the application filing date on or in connection with the goods/services in the application; and
- To the best of the signatory's knowledge and belief, the facts recited in the application are accurate.

☑ To the best of the signatory's knowledge and belief, no other persons, except, if applicable, concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services of such other persons, to cause confusion or mistake, or to deceive.

☑ To the best of the signatory's knowledge, information, and belief, formed after an inquiry reasonable under the circumstances, the allegations and other factual contentions made above have evidentiary support.

☑ The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any registration resulting therefrom, declares that all statements made of his/her own knowledge are true and all statements made on information and belief are believed to be true.

Declaration Signature

Signature: /lsvanlandingham/ Date: 07/09/2024
Signatory's Name: Leander S. VanLandingham III
Signatory's Position: Attorney of record, Arizona Bar member
Signatory's Phone Number: 928-453-0293
Signature method: Signed directly within the form
Payment Sale Number: 98638859
Payment Accounting Date: 07/09/2024

Serial Number: 98638859
Internet Transmission Date: Tue Jul 09 12:27:35 ET 2024
TEAS Stamp: USPTO/FTK-X.XX.XXX.XX-202407091227362735
52-98638859-870d3ace8228569a3e4c95615cad
e16b86f8b7bd7816e737f30164b2a18d26c69-CC
-27359525-20240709120024875228

GlucoSober

GlucoSober

User: Rebecca Choi

Statistics for Case 98638859						
#	Search	Total Marks	Dead Marks	Live Viewed Docs	Live Viewed Images	Status/Search Duration
1	SN:98579673	1	0	1	0	0:00
2	CM:/.*gl+[ou][ckq]{1,2}o.*/ AND LD:true	310	0	310	0	0:00
3	CM:/.*v[ae][sz]t.*/ AND LD:true	8677	0	0	0	0:00
4	CM:/.*[sz]ob[eoui]r.*/ AND LD:true	370	0	370	0	0:00
5	2 AND 3	1	0	1	0	0:00
6	2 AND 4	1	0	1	0	0:00
7	CM:/.*gl+[aeiouy]+w*[ckq]+[eaou]+w*.*/ AND LD:true	1021	0	0	0	0:00
8	CM:/.*[vw][aeiouy]+[sz]+e{0,1}[td].*/ AND LD:true	24356	0	0	0	0:00
9	CM:/.*[szc][aeiouy]+w*b+[aeiouy]+r.*/ AND LD:true	5258	0	0	0	0:00
10	7 AND 8	1	0	1	0	0:00
11	7 AND 9	3	0	3	0	0:00
12	CM:/.*gl.*[ckq].*v.*[sz].*/ AND LD:true	9	0	9	0	0:00
13	CM:/.*gl.*[ckq].*[sz].*b.*/ AND LD:true	5	0	5	0	0:00
14	CM:/.*gl.*[ckq].*[sz].*b.* AND LD:true.*/ AND LD:true	0	0	0	0	0:00
15	CM:/.*gl.*[ckq].*[sz].*b.*r.*/ AND LD:true	2	0	2	0	0:00
16	CM:/.*m[iey]+[td]+[eaou]+w*.*/ AND LD:true	18944	0	0	0	0:00
17	CM:/.*[qkc][iey]+n.*/ AND LD:true	109839	0	0	0	0:00
18	CM:/.*n[aeiouy]+r+[eaou]+w*.*/ AND LD:true	16876	0	0	0	0:00
19	9and 16	135230	0	0	0	0:00
20	9and 17	225243	0	0	0	0:00
21	9and 18	133179	0	0	0	0:00
22	9 AND 18	17	0	17	0	0:00
23	9 AND 17	110	0	110	0	0:00
24	9 AND 16	14	0	14	0	0:00
25	CM:/.*m.*t.*[sz].*b.*r.*/ AND LD:true	33	0	33	0	0:00
26	CM:/.*[ckq].*n.*[sz].*b.*r.*/ AND LD:true	143	0	143	0	0:00
27	CM:/.*n.*+r.*[sz].*b.*r.*/ AND LD:true	45	0	45	0	0:00
28	16 AND 17	464	0	464	0	0:00
29	CM:/.*[ckq].*n.*m.*t.*/ AND LD:true	1975	0	0	0	0:00
30	CC:005 AND 29	703	0	0	0	0:00

Statistics for Case 98638859						
#	**Search**	**Total Marks**	**Dead Marks**	**Live Viewed Docs**	**Live Viewed Images**	**Status/Search Duration**
31	CC:005 AND 3	2345	0	0	0	0:00
32	CC:005 AND 7	680	0	0	0	0:00
33	CC:005 AND 8	6825	0	0	0	0:00
34	CC:005 AND 9	1947	0	0	0	0:00
35	CM:/.*qin.*/ AND LD:true	1483	0	0	0	0:00
36	CM:/.*mito.*/ AND LD:true	538	0	538	0	0:00
37	CM:/.*neuro.*/ AND LD:true	2147	0	0	0	0:00
38	CC:005 AND (35 36 37)	1984	0	0	0	0:00
39	CC:005 AND 35	191	0	191	0	0:00
40	CC:005 AND 36	251	0	251	0	0:00
41	CC:005 AND 37	1543	0	0	0	0:00

Session started 11/14/2024 3:09 pm
Session ended 11/15/2024 10:57 am
Total search duration 0.00
Session duration 47 minutes 37 seconds
Adjacency Level 1
Near Level 1

Trademark Snap Shot Amendment & Mail Processing Stylesheet
(Table presents the data on Amendment & Mail Processing Complete)

OVERVIEW

SERIAL NUMBER	98638859	FILING DATE	07/09/2024
REG NUMBER	0000000	REG DATE	N/A
REGISTER	PRINCIPAL	MARK TYPE	TRADEMARK
INTL REG #	N/A	INTL REG DATE	N/A
TM ATTORNEY	CHOI, REBECCA	L.O. ASSIGNED	118

PUB INFORMATION

RUN DATE	11/15/2024
PUB DATE	N/A
STATUS	680-APPROVED FOR PUBLICATION
STATUS DATE	11/15/2024
LITERAL MARK ELEMENT	GLUCOSOBER

DATE ABANDONED	N/A	DATE CANCELLED	N/A
SECTION 2F	NO	SECTION 2F IN PART	NO
SECTION 8	NO	SECTION 8 IN PART	NO
SECTION 15	NO	REPUB 12C	N/A
RENEWAL FILED	NO	RENEWAL DATE	N/A
DATE AMEND REG	N/A		

FILING BASIS

FILED BASIS		CURRENT BASIS		AMENDED BASIS	
1 (a)	NO	1 (a)	NO	1 (a)	NO
1 (b)	YES	1 (b)	YES	1 (b)	NO
44D	NO	44D	NO	44D	NO
44E	NO	44E	NO	44E	NO
66A	NO	66A	NO		
NO BASIS	NO	NO BASIS	NO		

MARK DATA

STANDARD CHARACTER MARK	YES
LITERAL MARK ELEMENT	GLUCOSOBER
MARK DRAWING CODE	4-STANDARD CHARACTER MARK
COLOR DRAWING FLAG	NO

CURRENT OWNER INFORMATION

PARTY TYPE	10-ORIGINAL APPLICANT

NAME	Bonerge Lifescience (Hunan) Co., Ltd.
ADDRESS	Bldg#7B, Depu Parkview, E&D Zone Changsha, Hunan, 414000
ENTITY	99-limited company (ltd.)
CITIZENSHIP	China

GOODS AND SERVICES

INTERNATIONAL CLASS	005
DESCRIPTION TEXT	Dietary beverage supplements for human consumption in liquid and dry mix form for therapeutic purposes; Dietary supplement drink mixes; Dietary supplemental drinks; Dietary supplements; Dietary supplements for animals; Dietary supplements for humans; Dietary supplements for lowering glucose levels; Dietary supplements in the form of capsules, tablets, caplets, powder, liquids, syrups, gummies, gels and soft chews; Dietary supplements in the nature of weight loss powders; Dietary and nutritional supplements; Dietary and nutritional supplements used for weight loss; Dietary food supplements; Food supplements; Herbal supplements; Meal replacement bars for weight loss purposes; Nutritional food additives for medical purposes in the nature of natural food extracts derived from plants, fruits and vegetables; Nutritional supplements; Nutritional supplements for lowering glucose levels; Nutritional supplements in the form of capsules, tablets, caplets, powder, liquids, syrups, gummies, gels and soft chews; Plant extracts, other than essential oils, for medical, veterinary and pharmaceutical purposes; Plant extracts, other than essential oils, for pharmaceutical purposes; Plant and herb extracts, other than essential oils, for medicinal purposes; Powdered nutritional supplement concentrate; Powdered nutritional supplement drink mix; Glucose dietary supplements; Natural dietary supplements; Nutraceuticals for use as a dietary supplement; Nutritional and dietary supplements formed and packaged as bars; Nutritional supplement meal replacement bars for boosting energy; Vitamins and dietary food supplements for animals

GOODS AND SERVICES CLASSIFICATION

INTERNATIONAL CLASS	005	FIRST USE DATE	NONE	FIRST USE IN COMMERCE DATE	NONE	CLASS STATUS	6-ACTIVE

MISCELLANEOUS INFORMATION/STATEMENTS

CHANGE IN REGISTRATION	NO

PROSECUTION HISTORY

DATE	ENT CD	ENT TYPE	DESCRIPTION	ENT NUM
11/15/2024	CNSA	P	APPROVED FOR PUB - PRINCIPAL REGISTER	008
11/15/2024	XAEC	I	EXAMINER'S AMENDMENT ENTERED	007
11/15/2024	GNEN	O	NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED	006
11/15/2024	GNEA	F	EXAMINERS AMENDMENT E-MAILED	005
11/15/2024	CNEA	R	EXAMINERS AMENDMENT -WRITTEN	004
11/14/2024	DOCK	D	ASSIGNED TO EXAMINER	003
07/09/2024	NWOS	I	NEW APPLICATION OFFICE SUPPLIED DATA ENTERED	002
07/09/2024	NWAP	I	NEW APPLICATION ENTERED	001

CURRENT CORRESPONDENCE INFORMATION

ATTORNEY	L. S. VanLandingham III

CORRESPONDENCE ADDRESS	L. S. VanLandingham III 91 Lakemaster Lane Lake Havasu City, AZ 86403
DOMESTIC REPRESENTATIVE	L. S. VanLandingham III

GlucoSober

Note To The File

Serial Number: 98638859 GLUCOSOBER
Date: 11/15/2024 2:06 pm
Created by: Rebecca Choi

Changed

- Issued Examiner's Amendment and Entered Changes

Discussed file with Attorney/Applicant

- via E-Mail

From: lee vanlandingham <lsvanlan@hotmail.com>
Sent: Friday, November 15, 2024 2:01 PM
To: Choi, Rebecca <Rebecca.Choi@uspto.gov>
Subject: Re: Proposed Examiner's Amendment - Bonerge Lifescience Applications

CAUTION: This email has originated from a source outside of USPTO.**PLEASE CONSIDER THE SOURCE** before responding, clicking on links, or opening attachments.

Dear Examiner Choi,

Yes, the proposed amendment to the identification of goods is acceptable for all seven applications.

Please make the change by Examiner's Amendment.

Thanks.

Lee

L. S. VAN LANDINGHAM, III

Attorney for Applicant

91 Lakemaster Lane

Lake Havasu City, AZ 86403

(928) 453-0293

(928) 514-2280

Lsvanlan@hotmail.com

From: Choi, Rebecca <Rebecca.Choi@uspto.gov>
Sent: Friday, November 15, 2024 8:31 AM
To: Lsvanlan@hotmail.com <Lsvanlan@hotmail.com>
Subject: Proposed Examiner's Amendment - Bonerge Lifescience Applications

Dear L. S. VanLandingham III,

Good morning. I am the USPTO examining attorney assigned to the following Application Serial Nos.:

- 98689390 ULTRAURO
- 98657371 QINMITO
- 98656072 NEUROSOBER
- 98656028 QINSOBER
- 98655908 MITOSOBER
- 98638859 GLUCOSOBER
- 98579673 GLUCOVEST

After reviewing your applications, it appears there is an issue that needs to be addressed before the mark is ready for publication.

The wording “Nutritional food additives for medical purposes in the nature of natural food extracts derived from plants, fruits and/or vegetables” in the identification of goods is indefinite and must be clarified because “and/or” does not indicate particular goods. The following amendment is suggested: “**Nutritional food additives for medical purposes in the nature of natural food extracts derived from plants, fruits and vegetables**.” All other identifications are acceptable without amendment.

To resolve this issue, please give me a call at 571-272-2108, leave a voice message, or respond to this email granting me permission to make the specified changes. Should you choose to respond by email, please note that all relevant e-mail communications will be placed in the official application record. If I do not hear from you by Tuesday, I will issue an Office Action with the requirements. Thank you.

/Rebecca C./

Examining Attorney – Trademark Law Office 118

United States Patent and Trademark Office

571-272-2108

rebecca.choi@uspto.gov

To: L. S. VanLandingham III(Lsvanlan@hotmail.com)
Subject: U.S. Trademark Application Serial No. 98638859 - GLUCOSOBER
Sent: November 15, 2024 02:21:00 PM EST
Sent As: tmng.notices@uspto.gov

Attachments

United States Patent and Trademark Office (USPTO)
Office Action (Official Letter) About Applicant's Trademark Application

U.S. Application Serial No. 98638859

Mark: GLUCOSOBER

Correspondence Address:
L. S. VanLandingham III
91 Lakemaster Lane
Lake Havasu City AZ 86403
United States

Applicant: Bonerge Lifescience (Hunan) Co., Ltd.

Reference/Docket No. N/A

Correspondence Email Address: Lsvanlan@hotmail.com

EXAMINER'S AMENDMENT

Issue date: November 15, 2024

USPTO database searched; no conflicting marks found. The trademark examining attorney has searched the USPTO database of registered and pending marks and has found no conflicting marks that would bar registration under Trademark Act Section 2(d). 15 U.S.C. §1052(d); TMEP §704.02.

Application has been amended as shown below. As agreed to by L. S. VanLandingham III on November 15, 2024, the examining attorney has amended the application as shown below. Please notify the examining attorney immediately of any objections. TMEP §707. Otherwise, no response is required. *Id*. In addition, applicant is advised that amendments to the goods and/or services are permitted only if they clarify or limit them; amendments that add to or broaden the scope of the goods and/or services are not permitted. 37 C.F.R. §2.71(a).

The identification of goods is amended to read as follows: "Dietary beverage supplements for human consumption in liquid and dry mix form for therapeutic purposes; Dietary supplement drink mixes; Dietary supplemental drinks; Dietary supplements; Dietary supplements for animals; Dietary supplements for humans; Dietary supplements for lowering glucose levels; Dietary supplements in the

form of capsules, tablets, caplets, powder, liquids, syrups, gummies, gels and soft chews; Dietary supplements in the nature of weight loss powders; Dietary and nutritional supplements; Dietary and nutritional supplements used for weight loss; Dietary food supplements; Food supplements; Herbal supplements; Meal replacement bars for weight loss purposes; Nutritional food additives for medical purposes in the nature of natural food extracts derived from plants, fruits and vegetables; Nutritional supplements; Nutritional supplements for lowering glucose levels; Nutritional supplements in the form of capsules, tablets, caplets, powder, liquids, syrups, gummies, gels and soft chews; Plant extracts, other than essential oils, for medical, veterinary and pharmaceutical purposes; Plant extracts, other than essential oils, for pharmaceutical purposes; Plant and herb extracts, other than essential oils, for medicinal purposes; Powdered nutritional supplement concentrate; Powdered nutritional supplement drink mix; Glucose dietary supplements; Natural dietary supplements; Nutraceuticals for use as a dietary supplement; Nutritional and dietary supplements formed and packaged as bars; Nutritional supplement meal replacement bars for boosting energy; Vitamins and dietary food supplements for animals." *See* TMEP §§1402.01, 1402.01(e).

All issues are now resolved. Please contact the undersigned should you have any questions.

/Rebecca Choi/
Rebecca Choi
Examining Attorney
LO118--LAW OFFICE 118
(571) 272-2108
Rebecca.Choi@uspto.gov

United States Patent and Trademark Office (USPTO)

USPTO OFFICIAL NOTICE

Office Action (Official Letter) has issued
on November 15, 2024 for
U.S. Trademark Application Serial No. 98638859

A USPTO examining attorney has reviewed your trademark application and issued an Office action. You may be required to respond to this Office action. Follow the steps below.

(1) Read the Office action. This email is NOT the Office action.

(2) Respond to the Office action, if a response is required. Respond by deadline using the Trademark Electronic Application System (TEAS). Your response must be received by the USPTO on or before 11:59 p.m. **Eastern Time** of the last day of the response period. Otherwise, your application will be abandoned. See the Office action itself regarding how to respond.

(3) Direct general questions about using USPTO electronic forms, the USPTO website, the application process, the status of your application, and whether there are outstanding deadlines to the Trademark Assistance Center (TAC).

After reading the Office action, address any question(s) regarding the specific content to the USPTO examining attorney identified in the Office action.

GENERAL GUIDANCE

- **Check the status of your application periodically** in the Trademark Status & Document Retrieval (TSDR) database to avoid missing critical deadlines.

- **Update your correspondence email address** to ensure you receive important USPTO notices about your application.

- **Beware of trademark-related scams**. Protect yourself from people and companies that may try to take financial advantage of you. Private companies may call you and pretend to be the USPTO or may send you communications that resemble official USPTO documents to trick you. We will never request your credit card number or social security number over the phone. Verify the correspondence originated from us by using your Serial Number in our database, TSDR, to confirm that it appears under the "Documents" tab, or contact the Trademark Assistance Center.

- **Hiring a U.S.-licensed attorney.** If you do not have an attorney and are not required to

have one under the trademark rules, we encourage you to hire a U.S.-licensed attorney specializing in trademark law to help guide you through the registration process. The USPTO examining attorney is not your attorney and cannot give you legal advice, but rather works for and represents the USPTO in trademark matters.

EXHIBIT 20

Nature's Fusions

Home / Supplements / Nutri Dihydroberberine+ Supplement With Ceylon Cinnamon 200mg – 60 Capsules





Rewards Program

Nature's Fusions

$34.99

1 ADD TO CART

Description Reviews

60 capsules per bottle
Each capsule contains 200mg Dihydroberberine and 400mg Organic Cinnamon Ceylon Extract

Product Benefits:

- **PREMIUM QUALITY INGREDIENTS**: Our Premium Dihydroberberine with Organic Ceylon Cinnamon is crafted with the highest quality products. Each serving provides a potent dosage of 200mg to ensure maximum effectiveness.
- **60 DIHYDROBERBERINE CAPSULES**: 60 Day Supply, Take 1 daily – 200mg Dihydroberberine with 400mg Organic Cinnamon Ceylon.
- **Metabolic Support***

Directions: Take one capsule daily.

3rd party Lab Tested in the USA: We have our own FDA registered Food-Grade facility in the USA. All our products are 3rd-Party tested to guarantee purity. **Satisfaction Guaranteed**: At Nutri we guarantee almost everything Forever.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease

Related products









Rewards Program

Nature's Fusions

0

CHONDROITIN COMPLETE JOINT COMPLEX W/ MSM+ 3025 MG – 120 COUNT
$26.99
Add to cart

4/8 G UNFLAVORED POWDER – 360 G TUB
$69.99
Add to cart

MESOZEAXANTHIN VISION COMPLEX WITH ZINC 20/12 MG – 60 COUNT
$19.99
Add to cart

POWERFUL SENOLYTIC ACTIVATOR, ANTIOXIDA BRAIN SUPPORT – NAT POLYPHENOLS – 32 CO
$39.99
Add to cart

Nature's Fusions

Nature's Fusions was founded in 2009 by brothers David and CJ Peterson. What began as a small essential oil distribution company for family and friends, quickly grew to what it is today – a leading provider of 100% pure, natural, and authentic essential oils and other all-natural products. Whether you're new to essential oils or a seasoned aficionado, we're here to assist you on your journey to optimal wellness.

CUSTOMER CARE
- My Account
- Order Status
- Shipping & Return Policy
- Medical Disclosures
- Terms And Conditions
- Privacy Statement

QUICK LINKS
- Blend Comparison Chart
- Contact Us
- Site Map
- FAQs
- Certifications And Reports
- Affiliates Program

DISCOVER
- Our Story
- Wholesale
- White Label/Private Label
- Military & Disability
- The Forever Guarantee

Rewards Program

Nature's Fusions

support@naturesfusions.com
57 N 1380 W, Orem, UT 84057

© 2024 Nature's Fusions, LLC; all rights reserved.

Rewards Program

EXHIBIT 21

Nature's Fusions

Home / Supplements / Nutri Dihydroberberine+ Supplement With Ceylon Cinnamon 200mg – 60 Capsules



Nutri Dihydroberberine+ Supplement With Ceylon Cinnamon 200mg – 60 Capsules

$34.99

1 ADD TO CART

Rewards Program

Nature's Fusions

Description Reviews

60 capsules per bottle
Each capsule contains 200mg Dihydroberberine and 400mg Organic Cinnamon Ceylon Extract

Product Benefits:

- **PREMIUM QUALITY INGREDIENTS**: Our Premium Dihydroberberine with Organic Ceylon Cinnamon is crafted with the highest quality products. Each serving provides a potent dosage of 200mg to ensure maximum effectiveness.
- **60 DIHYDROBERBERINE CAPSULES**: 60 Day Supply, Take 1 daily – 200mg Dihydroberberine with 400mg Organic Cinnamon Ceylon.
- **Metabolic Support***

Directions: Take one capsule daily.

3rd party Lab Tested in the USA: We have our own FDA registered Food-Grade facility in the USA. All our products are 3rd-Party tested to guarantee purity. **Satisfaction Guaranteed**: At Nutri we guarantee almost everything Forever.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease

Related products



NUTRI GLUCOSAMINE CHONDROITIN COMPLETE JOINT COMPLEX W/ MSM+ 3025 MG – 120 COUNT

$26.99

Add to cart



NUTRI COLOSTRUM + COLLAGEN 4/8 G UNFLAVORED POWDER – 360 G TUB

$69.99

Add to cart



NUTRI LUTEIN, ZEAXANTHIN & MESOZEAXANTHIN VISION COMPLEX WITH ZINC 20/12 MG – 60 COUNT

$19.99

Add to cart




NUTRI FISETIN 500MG · POWERFUL SENOLYTIC ACTIVATOR, ANTIOXIDA BRAIN SUPPORT – NAT POLYPHENOLS – 32 CO

$39.99

Add to cart

Rewards Program



Rewards Program